



CSMJ

THE JOURNAL OF BAŞAKŞEHİR ÇAM AND SAKURA CITY HOSPITAL



Figure 1. Three dimensional reconstruction of contrast enhanced computed tomography scan demonstrating left external iliac artery thrombosis




Figure 2. (a-c) In functional magnetic resonance imaging, it was seen that contralateral cortical motor areas were activated when both, hand actively moved and the other hand contracted involuntarily



April

2023 Volume: 3 Issue: 1

C
A
M
&
S
A
K
U
R
A
M
E
D
I
C
A
L
J
O
U
R
N
A
L



Editor-in Chief

Merih Çetinkaya

Department of Neonatology, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

drmerih@yahoo.com

ORCID ID: 0000-0002-7344-8637

Editorial Secretary

Kamuran Ziyaretli Şanlı

Department of Microbiology and Clinical Microbiology, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

kamuran67@gmail.com

ORCID ID: 0000-0003-0814-5637

Deputy Editors

Ahmet Güler

Department of Cardiology, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

ahmetguler01@yahoo.com.tr

ORCID ID: 0000-0002-0963-9658

Alper Gümüş

Department of Biochemistry, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

dralpergumus@gmail.com

ORCID ID: 0000-0002-4453-6339

Bekir Tuğcu

Department of Neurosurgery, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

tugcubekir@gmail.com

ORCID ID: 0000-0003-0385-0054

Didem Karaçetin

Department of Radiation Oncology, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

didemkaracetin@gmail.com

ORCID ID: 0000-0001-5359-5958

Esra Şüheda Hatipoğlu

Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

esuheda@yahoo.com

ORCID ID: 0000-0001-8361-8866

İlgin Özden

Department of Hepatopancreatobiliary Surgery and Liver Transplantation, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

iozden@hotmail.com

ORCID ID: 0000-0001-7360-628X

Nevra Dursun Kepkep

Department of Pathology, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

durnevra@gmail.com

ORCID ID: 0000-0001-8076-7911

Nilüfer Çetinkaya Kocadal

Department of Gynecology and Gynecologic Oncology, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

cetinkayanilufer@gmail.com

ORCID ID: 0000-0001-9183-3558

Ömür Günaldı

Department of Neurosurgery, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

omurgunaldi@gmail.com

ORCID ID: 0000-0001-5071-1319

Özgür Kılıçkesmez

Department of Radiology, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

okilickesmez@yahoo.com

ORCID ID: 0000-0003-4658-2192

Ramazan Güven

Department of Emergency Medicine, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

dramazanguven@gmail.com

ORCID ID: 0000-0003-4129-8985

Serkan Sarı

Department of General Surgery, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

drserkansari@yahoo.com

ORCID ID: 0000-0003-2918-1776

Editorial Board

Associate Editors

Ali İhsan Dokucu

Department of Pediatric Surgery, University of Health Sciences
Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Turkey
aidokucu@gmail.com
ORCID ID: 0000-0002-1162-5140

Ayşe Esra Karakoç

Department of Medical Microbiology, Ankara Training and Research
Hospital, Ankara, Turkey
aesrakarakoc@gmail.com
ORCID ID: 0000-0001-6332-1109

Birsen Gökyiğit

Department of Ophtalmology, İstanbul Yeni Yüzyıl University, İstanbul,
Turkey
bgokiyigit@hotmail.com
ORCID ID: 0000-0002-4154-4106

Fuat Emre Canpolat

Department of Pediatrics, Division of Neonatology, University of
Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey
femrecan@gmail.com
ORCID ID: 0000-0001-9307-3003

Meral Günaldi

Department of Medical Oncology, Aydın University, Faculty of
Medicine, İstanbul, Turkey
meralgunaldi@gmail.com
ORCID ID: 0000-0002-5496-9824

Özlem Altuntaş Aydın

Department of Infectious Disease and Microbiology, University of
Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital,
İstanbul, Turkey
ozlemaa@gmail.com
ORCID ID: 0000-0001-8035-1385

Soyhan Bağcı

Department of Neonatology and Pediatric Intensive Care, Children's
Hospital, University of Bonn, Bonn, Germany
Soyhan.bagci@ukbonn.de
ORCID ID: 0000-0003-1005-665X

Yıldız Okuturlar

Department of Internal Medicine, Acıbadem University, Faculty of
Medicine, Acıbadem Atakent Hospital, İstanbul, Turkey
y.okuturlar@gmail.com
ORCID ID: 0000-0002-1994-0014

Statistics Editors

Ali Ayçiçek

Department of Pediatric Hematology, University of Health Sciences
Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey
ayciceka@hotmail.com
ORCID ID: 0000-0001-8951-4750

Erkut Öztürk

Department of Pediatric Cardiology, University of Health Sciences
Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey
erkut_ozturk@yahoo.com
ORCID ID: 0000-0002-1762-3269

Language Editor

Banu Arslan

Department of Emergency Medicine, University of Health Sciences
Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey
dr.banuarslan@gmail.com
ORCID ID: 0000-0003-0982-5351

English Editing

Provided by Galenos for accepted articles

Perspective & Images Editor

Aytül Hande Yardımcı

Department of Radiology, University of Health Sciences Turkey,
Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey
yahandeeo@yahoo.com
ORCID ID: 0000-0002-5163-9141

Anesthesiology and Reanimation

Section Editor: Funda Gümüş Özcan, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Antigona Hasani, University of Pristina, Faculty of Medicine, Pristina, Kosovo

Dilek Kazancı, Ankara City Hospital, Ankara, Turkey

Fevzi Toraman, Acıbadem Mehmet Ali Aydınlar University, Faculty of Medicine, İstanbul, Turkey

Kemal Tolga Saraçoğlu, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey

Onur Demirci, Mayo Clinic, Minnesota, United States

Tülin Öztürk, Celal Bayar University, Faculty of Medicine, Manisa, Turkey

Biochemistry

İlhan Yaylım, İstanbul University, İstanbul Faculty of Medicine, İstanbul, Turkey

Murat Can, Bülent Ecevit University, Faculty of Medicine, Zonguldak, Turkey

Mevlüt Sait Keleş, Üsküdar University, Faculty of Medicine, İstanbul, Turkey

Cardiology

Abdullah Orhan Demirtaş, Adana City Hospital, Adana, Turkey

Alev Kılıçgedik, Kartal Koşuyolu Cardiovascular Research and Training Hospital, İstanbul, Turkey

Ali Kemal Kalkan, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey

Can Yücel Karabay, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey

Taylan Akgün, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Cardiovascular Surgery

Section Editor: Nihan Kayalar, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Mehmed Yanartaş, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Sameh Said, University of Minnesota, Faculty of Medicine, Minneapolis, United States

Suat Nail Ömeroğlu, İstanbul University, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey

Süleyman Yazıcı, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Chest Disease

Section Editor: Mehmet Akif Özgül, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Ekrem Cengiz Seyhan, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey

Gamze Kırkıl, Fırat University, Faculty of Medicine, Elazığ, Turkey

Mehmet Atilla Uysal, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey

Sibel Yurt, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Critical Care Medicine

Section Editor: Güldem Turan, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Işıl Özkoçak, Ankara City Hospital, Ankara, Turkey

Namigar Turgut, University of Health Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Turkey

Nimet Şenoğlu, Tepecik Training and Research Hospital, İzmir, Turkey

Tuğhan Utku, Yeditepe University, Faculty of Medicine, İstanbul, Turkey

Dermatology

Section Editor: Zafer Türkoğlu, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Didem Didar Balcı, Tepecik Training and Research Hospital, İzmir, Turkey

Burce Can, Sultan Abdulhamid Han Training and Research Hospital, İstanbul, Turkey

Filiz Topaloğlu Demir, Medipol University, Faculty of Medicine, İstanbul, Turkey

İlkin Zindancı, Ümraniye Training and Research Hospital, İstanbul, Turkey

Emergency Medicine

Ayhan Akoz, Adnan Menderes University, Faculty of Medicine, Aydın, Turkey

Burcu Genç Yavuz, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey

İsmail Tayfur, İlhan Varank Training and Research Hospital, İstanbul, Turkey

Mücahit Kapçı, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Özgür Söğüt, University of Health Sciences Turkey, Haseki Training and Research Hospital, İstanbul, Turkey

Shikha Tandon, Fortis Hospital, New Delhi, India

Endocrinology and Metabolism

Hakan Korkmaz, Süleyman Demirel University, Faculty of Medicine, Isparta, Turkey

Mahmut Muzaffer İlhan, Medipol Çamlıca Hospital, İstanbul, Turkey

Meral Mert, University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

Mutlu Niyazoğlu, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Editorial Board

Sema Çiftçi, University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

Family Medicine

Section Editor: Hilal Özkaya, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Kamile Marakoğlu, Selçuk University, Faculty of Medicine, Konya, Turkey

Mehmet Özen, Antalya Training and Research Hospital, Antalya, Turkey

Seçil Güner Arıca, University of Health Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Turkey

General Surgery

Section Editor of Surgical Oncology: Soykan Arıkan, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Section Editor of Gastrointestinal Surgery: Kıvanç Derya Peker, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Section Editor of General Surgery: Hasan Bektaş, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Abdul Cem İbiş, İstanbul University, Faculty of Medicine, İstanbul, Turkey

Ali Orhan Bilge, Koç University, Faculty of Medicine, İstanbul, Turkey

Erdal Birol Bostancı, Ankara City, Hospital, Ankara, Turkey

Güralp Onur Ceyhan, Mehmet Ali Aydınlar Acıbadem University, Faculty of Medicine, İstanbul, Turkey

Halil Alış, Aydın University, Faculty of Medicine, İstanbul, Turkey

Orhan Ağcaoğlu, Koç University, Faculty of Medicine, İstanbul, Turkey

Timuçin Taner, Mayo Clinic, Minnesota, United States

Gynecologic Oncology

İbrahim Yalçın, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey

Murat Öz, Ankara City Hospital, Turkey

Mustafa Zelal Muallem, Charite Universitätsmedizin, Berlin, Germany

Onur Güralp, Carl von Ossietzky Oldenburg University, Oldenburg, Germany

Hematology

Section Editor: Mesut Ayer, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Güven Çetin, Bezmialem University, Faculty of Medicine, İstanbul, Turkey

Şebnem İzmir Güner, Gelişim University, Memorial Hospital, İstanbul, Turkey

Sinan Dal, Abdurrahman Yurtarlan Ankara Oncology Hospital, Ankara, Turkey

Hepatobiliary Surgery and Liver Transplantation

Acar Tüzüner, Ankara University, Faculty of Medicine, Ankara, Turkey

Bülent Aydın, Akdeniz University, Faculty of Medicine, Antalya, Turkey

Gürkan Öztürk, Atatürk University, Faculty of Medicine, Erzurum, Turkey

Sezai Yılmaz, İnönü University, Faculty of Medicine, Malatya, Turkey

Infectious Disease and Microbiology

Section Editor: Özlem Altuntaş Aydın, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Behice Kurtaran, Çukurova University, Faculty of Medicine, Adana, Turkey

Fatma Gümüşer, Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Kahramanmaraş, Turkey

Hayat Kumbasar Karaosmanoğlu, University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

Meliha Meriç Koç, Bezmialem University, Faculty of Medicine, İstanbul, Turkey

Internal Medicine

Section Editor: Zeynep Karaali, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Alma İdrizi, UHC Mother Teresa, Tirana, Albania

Banu Büyük, Kartal Lütfi Kırdar City Hospital, İstanbul, Turkey

Esra Ataoğlu, University of Health Sciences Turkey, Haseki Training and Research Hospital, İstanbul, Turkey

Sema Basat, Ümraniye Training and Research Hospital, İstanbul, Turkey

Tayyibe Saler, Adana City Hospital, Adana, Turkey

Medical Biology

Çiğdem Kekik, İstanbul University, Faculty of Medicine, İstanbul, Turkey

Fatma Oğuz Sarvan, İstanbul University, Faculty of Medicine, İstanbul, Turkey

Medical Microbiology

Bekir Sami Kocazeybek, İstanbul University, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey

Berrin Uzun, İzmir Tepecik Training and Research Hospital, İzmir, Turkey

İpek Kurtböke, University of Sunshine Coast, Sunshine Coast, Australia

Nuran Karabulut, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Onur Karatuna, EUCAST Development laboratory (EDL), Växjö, Sweden

Rıza Adaleti, İstanbul Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey

Sebahat Aksaray, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey

Medical Oncology

Ahmet Taner Sümbül, Başkent University, Faculty of Medicine, Adana Turkey

Emre Yıldırım, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey

Gökmen Umut Erdem, İstanbul University, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey

Neonatology

Ahmet Yağmur Baş, Etlik Zübeyde Hanım Women's Health Care, Training and Research Hospital, Ankara, Turkey

Hasan Sinan Uslu, University of Health Sciences Turkey, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey

Melek Akar, Tepecik Training and Research Hospital, İzmir, Turkey

Senem Alkan Özdemir, İzmir Dr. Behçet Uz Children's Hospital, İzmir, Turkey

Yekta Öncel, İzmir Katip Çelebi University, Faculty of Medicine, İzmir, Turkey

Nephrology

Section Editor: Gürsel Yıldız, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Funda Sarı, Akdeniz University, Faculty of Medicine, Antalya, Turkey

Rümeysa Kazancıoğlu, Bezmialem University, Faculty of Medicine, İstanbul, Turkey

Sinan Trabulus, İstanbul University, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey

Neurology

Section Editor: Ayça Özkul, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Ayhan Köksal, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Halil Lütfi Canat, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Murat Çabalar, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Ufuk Emre, İstanbul Training and Research Hospital, İstanbul, Turkey

Utku Oğan Akyıldız, Adnan Menderes University, Faculty of Medicine, Aydın, Turkey

Neurosurgery

Ali Dalgıç, Ankara City Hospital, Ankara, Turkey

Erhan Arslan, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey

Lütfi Şinasi Postalci, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Osman Tanrıverdi, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Yasin Temel, Maastrich University Faculty of Medicine, Maastricht, Netherlands

Nuclear Medicine

Ömer Aras, Memorial Sloan Kettering Cancer Center, New York, United States

Sanaz Behnia, Washington University, School of Medicine, Seattle, United States

Tevfik Fikret Çermik, İstanbul Training and Research Hospital, İstanbul, Turkey

Obstetrics and Gynecology

Section Editor: Burak Yücel, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Berna Aslan Çetin, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Levent Yaşar, University of Health Sciences Turkey, Bakırköy Dr. Sadi Kanuk Training and Research Hospital, İstanbul, Turkey

Mesut Abdülkerim Ünsal, Çanakkale Onsekiz Mart University, Faculty of Medicine, Çanakkale, Turkey

Mete Gürol Uğur, Gaziantep University, Faculty of Medicine, Gaziantep, Turkey

Murat Ekin, University of Health Sciences Turkey, University of Health Sciences Turkey, Bakırköy Dr. Sadi Kanuk Training and Research Hospital, İstanbul, Turkey

Onur Erol, Antalya Training and Research Hospital, Antalya, Turkey

Veli Mihmanlı, University of Health Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Turkey

Ophthalmology

Ali Demircan, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Hayyam Kıratlı, Hacettepe University, Faculty of Medicine, Ankara, Turkey

Pelin Kaynak, İstanbul, Turkey

Sezen Karakuş, Wilmer Eye Institute, John Hopkins University, Baltimore, United States

Tekin Yaşar, Beyoğlu Eye and Research Hospital, İstanbul, Turkey

Yusuf Yıldırım, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Orthopedics

Section Editor: Mehmet Bülent Balıoğlu, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Abdul Fettah Büyük, University of Missouri, School of Medicine, Columbia, MO, United States

Abdulhamid Misir, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Editorial Board

Bekir Eray Kılınç, Fatih Sultan Mehmet Training and Research Hospital, İstanbul, Turkey

Haluk Çelik, Ümraniye Training and Research Hospital, İstanbul, Turkey

Volkan Gür, Binali Yıldırım University, Faculty of Medicine, Erzincan, Turkey

Yaşar Mahsut Dinçel, Namık Kemal University, Faculty of Medicine, Tekirdağ, Turkey

Otolaryngology

Section Editor: Şahin Öğreden, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Hüseyin Deniz, Yeditepe University, Faculty of Medicine, İstanbul, Turkey

İbrahim Sayın, University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

Yalçın Alimoğlu, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Zahide Mine Yazıcı, University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

Pathology

Banu Yılmaz Özgüven, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Hülya Akgün, Erciyes University, Faculty of Medicine, Kayseri, Turkey

Kea-Teak Jang, Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea

Selvinaz Özkara, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Takuma Tajuri, Tokai University Hachioji Hospital, Tokyo, Japan

Esra Canan Kelten Talu, İzmir Tepecik Training and Research Hospital, İzmir, Turkey

Pediatrics

Section Editor: Şirin Güven, Prof. İhan Varank Training and Research Hospital, İstanbul, Turkey

Ali Kanık, Katip Çelebi University, Faculty of Medicine, İzmir, Turkey

Meltem Erol, Bağcılar Training and Research Hospital, İstanbul, Turkey

Özlem Bağ, Dr. Behçet Uz Training and Research Hospital, İzmir, Turkey

Vefik Arıca, Siirt University Faculty of Medicine, Siirt, Turkey

Pediatric Allergy

Emine Dibek Mısırlıoğlu, Ankara City Hospital, Ankara, Turkey

Ersoy Civelek, Ankara City Hospital, Ankara, Turkey

Zeynep Tamay, İstanbul University, İstanbul Faculty of Medicine, İstanbul, Turkey

Pediatric Cardiology

Section Editor: İbrahim Cansaran Tanıdır, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Antonia Sanchez Andres, Hospital General Universitario de Castellon, Castello, Spain

Celal Akdeniz, Medipol University, Faculty of Medicine, İstanbul, Turkey

Ehsan Aghaei Moghaddam, Tehran University Children's Medical Center, Tehran, Iran

Hakan Aykan, Hacettepe University, Faculty of Medicine, Ankara, Turkey

İsa Özyılmaz, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Pediatric Cardiovascular Surgery

Section Editor: Ali Can Hatemi, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Can Yerebakan, Children's National Hospital, Washington DC, United States

Hakan Ceyran, Kartal Koşuyolu Yüksek İhtisas Training and Research Hospital, İstanbul, Turkey

Işık Şenkaya Sağnak, Bursa Uludağ University, Faculty of Medicine, Bursa, Turkey

Okan Yıldız, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Yüksel Atay, Ege University, Faculty of Medicine, İzmir, Turkey

Pediatric Critical Care Medicine

Section Editor: Nurettin Onur Kutlu, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Ayşe Filiz Yetimakman, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey

Halit Çam, Sancaktepe Prof. Dr. İhan Varank Training and Research Hospital, İstanbul, Turkey

Muhterem Duyu, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, İstanbul, Turkey

Pediatric Endocrinology

Bumin Dündar, İzmir Katip Çelebi University, Faculty of Medicine, İzmir, Turkey

Erdal Eren, Bursa Uludağ University, Faculty of Medicine, Bursa, Turkey

Semra Çetinkaya, Dr. Sami Ulus Obstetrics and Pediatrics Training and Research Hospital, Ankara, Turkey

Pediatric Gastroenterology

Section Editor: Günsel Kutluk, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Gökhan Tümgör, Çukurova University, Faculty of Medicine, Adana, Turkey

Maşallah Baran, İzmir Katip Çelebi University, Faculty of Medicine, İzmir, Turkey

Pediatric Hematology

Ayşe Turhan, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, İstanbul, Turkey

Deniz Tuğcu, İstanbul University, Faculty of Medicine, İstanbul, Turkey

Hüseyin Tokgöz, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey

Suar Çakı Kılıç, Ümraniye Training and Research Hospital, İstanbul, Turkey

Zeynep Canan Özdemir, Osungazi University, Faculty of Medicine, Eskişehir, Turkey

Pediatric Immunology

Section Editor: Çiğdem Aydoğmuş, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Safa Barış, Marmara University, Faculty of Medicine, İstanbul, Turkey

Ferah Genel, Dr. Behçet Uz Training and Research Hospital, İzmir, Turkey

Pediatric Infectious Disease

Section Editor: Canan Caymaz, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Eda Karadağ Öncel, İzmir Tepecik Training and Research Hospital, İzmir, Turkey

Nevin Hatipoğlu, University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

Pediatric Metabolism

Section Editor: Hasan Önal, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Çiğdem Seher Kasapkara, Yıldırım Beyazıt University, Faculty of Medicine, Ankara, Turkey

Pediatric Nephrology

Section Editor: Sevgi Yavuz, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Alev Yılmaz, İstanbul University, İstanbul Faculty of Medicine, İstanbul, Turkey

Hasan Dursun, University of Health Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Turkey

Pediatric Neurology

Section Editor: İhsan Kafadar, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Andreas Hahn, Justus Liebig University, Giessen, Germany

Esra Gürkaş, Ankara City Hospital, Ankara, Turkey

Gülşen Köse, İstinye University, Faculty of Medicine, İstanbul, Turkey

Pediatric Psychiatry

Caner Mutlu, Bursa Uludağ University, Faculty of Medicine, Bursa, Turkey

Mustafa Çakan, Zeynep Kamil Maternity and Children's Training and Research Hospital, İstanbul, Turkey

Nuray Aktay Ayaz, İstanbul University, Faculty of Medicine, İstanbul, Turkey

Pediatric Romatology

Sezgin Şahin, İstanbul University, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey

Pediatric Surgery

Abdullah Yıldız, University of Health Sciences Turkey, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey

Çetin Ali Karadağ, University of Health Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Turkey

Melih Akın, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Muazzez Çevik, Mehmet Ali Aydınlar Acıbadem University, İstanbul, Turkey

Süleyman Çelebi, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Perinatology

Section Editor: İbrahim Polat, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Fikret Gökhan Göynümer, Düzce University, Faculty of Medicine, Düzce, Turkey

Hakan Erenel, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Mekin Sezik, Süleyman Demirel University, Faculty of Medicine, Isparta, Turkey

Muhittin Etfal Avcı, Antalya Memorial Hospital, Antalya, Turkey

Özhan Turan, University of Maryland, School of Medicine, Baltimore, United States

Psychiatry

Section Editor: Oya Güçlü, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Aslı Ener Darçın, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Cüneyt Evren, Bakırköy Mental Health Research and Teaching Hospital, İstanbul, Turkey

Fatih Öncü, Bakırköy Mental Health Research and Teaching Hospital, İstanbul, Turkey

Hüsni Erkmen, Üsküdar University, Faculty of Medicine, İstanbul, Turkey

Osama Abulseoud, Biomedical Research Center, Maryland, United States

Ömer Şenormancı, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey

Physical Medicine and Rehabilitation

Section Editor: Evrim Coşkun, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

Beril Özcan Doğu, University of Health Sciences Turkey, Şişli Hamidiye Etfal, Training and Research Hospital, İstanbul

Editorial Board

Domenica Corda, Polimedica San
Lanfranco, Pavia, Italy

Sevgi İkbali Afşar, Başkent University,
Faculty of Medicine, Ankara, Turkey

Sibel Ünsal Delioğlu, Ankara City Hospital,
Ankara, Turkey

Plastic and Reconstructive Surgery

İsmail Ermiş, İstanbul University, İstanbul
Faculty of Medicine, İstanbul, Turkey

Ömer Berkoz, İstanbul University, İstanbul
Faculty of Medicine, İstanbul, Turkey

Ufuk Emekli, İstanbul University, İstanbul
Faculty of Medicine, İstanbul, Turkey

Radiation Oncology

Aylin Fidan Korcum Şahin, Akdeniz
University, Faculty of Medicine, Antalya,
Turkey

Daniel Low, University of California, Los
Angeles, United States

Mahmut Özşahin, University of Lausanne
Medical Center, Lausanne, Switzerland

Ömür Karakoyun Çelik, Manisa Celal Bayar
University, Faculty of Medicine, Manisa,
Turkey

Vuslat Yürüt Çaloğlu, Trakya University,
Faculty of Medicine, Edirne, Turkey

Yasemin Bölükbaşı, Koç University, Faculty
of Medicine, İstanbul, Turkey

Radiology

Bengi Gürses, Koç University, Faculty of
Medicine, İstanbul, Turkey

Burak Koçak, University of Health Sciences
Turkey, Başakşehir Çam and Sakura City
Hospital, İstanbul, Turkey

Elif Hocaoğlu, University of Health
Sciences Turkey, Bakırköy Dr. Sadi Konuk
Training and Research Hospital, İstanbul,
Turkey

Neslihan Taşdelen, Yeditepe University,
Faculty of Medicine, İstanbul, Turkey

Serkan Arıbal, University of Health
Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu
City Hospital, İstanbul, Turkey

Renal Transplantation

Alp Gürkan, Okan University, Faculty of
Medicine, İstanbul, Turkey

Gürsel Yıldız, Yeni Yüzyıl University,
İstanbul, Turkey

İbrahim Berber, Acıbadem Mehmet Ali
Aydınlar University Faculty of Medicine,
İstanbul, Turkey

Süheyla Apaydın, Yeditepe University,
Faculty of Medicine, İstanbul, Turkey

Romatology

Section Editor: Cemal Bes, University of
Health Sciences Turkey, Başakşehir Çam
and Sakura City Hospital, İstanbul, Turkey

Sibel Zehra Aydın, Ottawa University,
Faculty of Medicine, Ottawa, Canada

Timuçin Kaşifoğlu, Eskişehir Osmangazi
University, Faculty of Medicine, Eskişehir,
Turkey

Umut Kalyoncu, Hacettepe University,
Faculty of Medicine, Ankara, Turkey

Vedat Hamuryudan, İstanbul Cerrahpaşa
University, Faculty of Medicine, İstanbul,
Turkey

Thoracic Surgery

Section Editor: Hasan Akın, University of
Health Sciences Turkey, Başakşehir Çam
and Sakura City Hospital, İstanbul, Turkey

Ali Cevat Kutluk, University of Health
Sciences Turkey, Başakşehir Çam and
Sakura City Hospital, İstanbul, Turkey

Alper Toker, West Virginia University,
Faculty of Medicine, Morgantown, United
States

Hacıali Kılıçgün, Abant İzzet Baysal
University, Faculty of Medicine, Bolu,
Turkey

Urology

Section Editor: Abdulluttalip Şimsek,
University of Health Sciences Turkey,
Başakşehir Çam and Sakura City Hospital,
İstanbul, Turkey

Alper Ötünçtemur, University of Health
Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu
City Hospital, İstanbul, Turkey

Feyzi Arda Atar, University of Health
Sciences Turkey, Bakırköy Dr. Sadi Konuk
Training and Research Hospital, İstanbul,
Turkey

Lütfi Canat, University of Health Sciences
Turkey, Başakşehir Çam and Sakura City
Hospital, İstanbul, Turkey

Sinan Levent Kireççi, University of Health
Sciences Turkey, Şişli Hamidiye Etfal
Training and Research Hospital, İstanbul,
Turkey

Yusuf Özlem İlbey, İzmir Tepecik Training
and Research Hospital, İzmir, Turkey

Zafer Gökhan Gürbüz, Adana City Hospital,
Adana, Turkey

Journal History

Cam ve Sakura Medical Journal (CSMJ) is an international, scientific, open access periodical published journal. It has independent, unbiased, and double-blinded peer-review principles. The journal is the official publication of the Basaksehir Cam & Sakura City Hospital. It is published three times per year (April, August, December). A special supplement including interesting, novel and attractive theme has also been published every year. The publication language of the journal is English.

Title: Cam ve Sakura Medical Journal

Official abbreviation: CSMJ, Csmedj

E-ISSN: 2791-8823

Free-of-Charge Publication

No fee is charged from the authors during the submission, evaluation and publication process. Journal practices, ethical rules, technical information and necessary forms are specified on the journal's web page.

The manuscripts must be submitted via the Manuscript Manager online article system, represented on the journal website.

Abstracting and Indexing

J-Gate, Türk Medline, EBSCO, Gale

Copyright

After the publication decision is made and accepted, the "Copyright Transfer Form" should be attached to the submissions. The form can also be downloaded from the journal's article submission system. The Copyright Transfer Form must be signed by all contributing authors and a scanned version of this wet-signed document must be submitted.

By citing the author and the journal at the same time, without any profit-making motive, and only for educational purposes, the readers can copy the article without the permission of the copyright holder.

Cam ve Sakura Medical Journal is an open access publication, and the journal's publication model is based on Budapest Open Access Initiative (BOAI) declaration. All published content is available online, free of charge at <https://csmedj.org/>. The journal's content is licensed under a Creative

Commons Attribution-NonCommercial (CC BY-NC-ND) 4.0 International License which permits third parties to share and adapt the content for non-commercial purposes by giving the appropriate credit to the original work.

Digital Archiving and Preservation Policy

Digital preservation is a set of processes and activities that ensure the retrieval and distribution of information now available in digital formats to guarantee long-term, perpetual access. The preservation policy includes the following measures:

Website Archiving

All of the electronic content (website, manuscript, etc.) is stored in three different sources. Content on a server is online and accessible to readers. A copy of the same content is preserved as a backup on two other sources. Should a server fail, other resources can be brought online, and the website is expected to be available in 24-36 hours.

Abstracting/Indexing Services

Our journal's Abstracting/Indexing services store essential information about articles. In addition, some of our journal's Abstracting/Indexing services archive metadata about the article and electronic versions of the articles. In this way, copies of articles are presented to the scientific community through these systems as an alternative to journals.

Issuing Body

Galenos Yayınevi Tic. Ltd. Sti.

Molla Gürani Mah. Kaçamak Sok. No: , 3409, Fındıkzade, İstanbul, Türkiye

Phone: +90 212 621 99 25

Fax: +90 212 621 99 27

E-mail: info@galenos.com.tr



Aims and Scope

Cam ve Sakura Medical Journal (CSMJ) is an international, scientific, open access periodical published journal. It has independent, unbiased, and double-blinded peer-review principles. The journal is the official publication of the Basakşehir Cam & Sakura City Hospital. It is published three times per year (April, August, December). A special supplement including interesting, novel and attractive theme has also been published every year. The publication language of the journal is English.

Cam & Sakura Medical Journal publishes original experimental or clinical research, review articles, case reports, technical reports, diagnostic puzzle, clinical images, video article, novel insight, and letters to the editor in the field of general medicine. Review articles will be only prepared by expert academicians upon invitation. The journal's target audience includes academics and expert physicians working in all fields of general medicine.

Cam ve Sakura Medical Journal does not charge any fees for submission, processing or publication of articles.

The editorial and publication process of the journal are shaped in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE), World Association of Medical Editors (WAME), Council of Science Editors (CSE), Committee on Publication Ethics (COPE), European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal is in conformity with the Principles of Transparency and Best Practice in Scholarly Publishing.

Cam ve Sakura Medical Journal is currently indexed in J-Gate.

Title: Cam ve Sakura Medical Journal

Official abbreviation: CSMJ, Csmedj

E-ISSN: 2791-8823

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Author (s) and copyright owner (s) grant access to all users for the articles published in the Cam ve Sakura Medical Journal as free of charge. Articles may be used provided that they are cited.

Open Access Policy is based on rules of Budapest Open Access Initiative (BOAI). By "open access" to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet

itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

Creative Commons

A Creative Commons license is a public copyright license that provides free distribution of copyrighted works or studies. Authors use the CC license to transfer the right to use, share or modify their work to third parties. This journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC-ND 4.0) which permits third parties to share and adapt the content for non-commercial purposes by giving the appropriate credit to the original work.

Open access is an approach that supports interdisciplinary development and encourages collaboration between different disciplines. Therefore, Cam ve Sakura Medical Journal contributes to the scientific publishing literature by providing more access to its articles and a more transparent review process.

Advertisement Policy

Potential advertisers should contact the Editorial Office. Advertisement images are published only upon the Editor-in-Chief's approval.

Material Disclaimer

Statements or opinions stated in articles published in the journal do not reflect the views of the editors, editorial board and/or publisher; The editors, editorial board and publisher do not accept any responsibility or liability for such materials. All opinions published in the journal belong to the authors.

Contact

Editorial Office

Address: Başakşehir Cam and Sakura City Hospital, Başakşehir Olimpiyat Bulvarı Yolu, 34480 Başakşehir, İstanbul/Turkey

E-mail: info@csmedj.org

Publisher Info

Galenos Publishing House

Address: Molla Gürani Mahallesi Kaçamak Sokak No: , 34093 Fındıkzade - İstanbul/Turkey

Phone: +90 (212) 621 99 25

Fax: +90 (212) 621 99 27

E-mail: info@galenos.com.tr

Peer- Review

Submission is considered on the conditions that papers are previously unpublished and are not offered simultaneously elsewhere; that authors have read and approved the content, and all authors have also declared all competing interests; and that the work complies with the Ethical Approval and has been conducted under internationally accepted ethical standards. If ethical misconduct is suspected, the Editorial Board will act in accordance with the relevant international rules of publication ethics (i.e., COPE guidelines).

Editorial policies of the journal are conducted as stated in the rules recommended by the Council of Science Editors and reflected in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. Accordingly, authors, reviewers, and editors are expected to adhere to the best practice guidelines on ethical behavior contained in this statement.

Submitted manuscripts are subjected to double-blinded peer-review. The scientific board guiding the selection of the papers to be published in the journal consists of elected specialists of the journal and, if necessary, selected from national and international experts in the relevant field of research. All manuscripts are reviewed by the editor, section associate editors and at least three internal and external expert reviewers. All research articles are interpreted by a statistical editor as well.

Human and Animal Rights

For the experimental, clinical and drug human studies, approval by ethical committee and a statement on the adherence of the study protocol to the international agreements (World Medical Association Association of Helsinki "Ethical Principles for Medical Research Involving Human Subjects," amended October 2013) are required. In experimental animal studies, the authors should indicate that the procedures followed were by animal rights (Guide for the care and use of laboratory animals), and they should obtain animal ethics committee approval. The Ethics Committee approval document should be submitted to the Cam ve Sakura Medical Journal (CSMJ) together with the manuscript.

The approval of the ethics committee, statement on the adherence to international guidelines mentioned above and that the patient's informed consent is obtained should be indicated in the `Material and Method` section and is required for case reports whenever data/media used could reveal the identity of the patient. The declaration of the conflict of interest between authors, institutions, acknowledgement of any financial or material support, aid is mandatory for authors submitting a manuscript, and the statement should appear at the end of the manuscript. Reviewers are required to report if any potential conflict of interest exists between the reviewer and authors, institutions.

Plagiarism and Ethical Misconduct

This journal uses "iThenticate" to screen all submissions for plagiarism before publication.

It is essential that authors avoid all forms of plagiarism and ethical misconduct as represented below.

Plagiarism: To Republish whole or part of a content in another author's publication without attribution.

Fabrication: To publish data and findings/results that do not exist.

Duplication: Using data from another publication that includes republishing an article in different languages.

Salamisation: Creating multiple publications by supernaturally splitting the results of a study.

Data Manipulation/Falsification: Manipulating or deliberately distorting research data to give a false impression.

We disapprove of such unethical practices as plagiarism, fabrication, duplication, data manipulation/falsification and salamisation and efforts to influence the review process with such practices as gifting authorship, inappropriate acknowledgements, and references in line with the COPE flowcharts.

Submitted manuscripts are also subjected to the evaluation of plagiarism, duplicate publication by automatic software. Authors are obliged to acknowledge if they published study results in whole or in part in the form of abstracts.

A. DUTIES OF PUBLISHER:**Handling of unethical publishing behaviour**

The publisher will take all appropriate measures to modify the article in question, in close cooperation with the editors, in cases of alleged or proven scientific misconduct, fraudulent publication, or plagiarism. This includes the prompt publication of an erratum, disclosure, or retraction of the affected work in the most severe case. Together with the editors, the publisher will take reasonable steps to detect and prevent the publication of articles in which research misconduct occurs and will under no circumstances promote or knowingly allow such abuse to occur.

Editorial Autonomy

Cam ve Sakura Medical Journal (CSMJ) is committed to ensuring the autonomy of editorial decisions without influence from anyone or commercial partners.

Intellectual Property and Copyright

Cam ve Sakura Medical Journal (CSMJ) protects the property and copyright of the articles published in the journal and maintains each article's published version of the record. The journal provides the integrity and transparency of each published article.

Scientific Misconduct

Cam ve Sakura Medical Journal (CSMJ)'s publisher always takes all appropriate measures regarding fraudulent publication or plagiarism.

Peer Review, Publication Ethics and Malpractice Statement

B. DUTIES OF EDITORS:**Decision on Publication and Responsibility**

The editor of the journal keeps under control everything in the journal and strives to meet the needs of readers and authors. The editor is also responsible for deciding which articles submitted to the journal should be published and guided by the policies subjected to legal requirements regarding libel, copyright infringement, and plagiarism. The editor might discuss with reviewers while making publication decisions. The editor is responsible for the contents and overall quality of the publication. Editor ought to provide a fair and appropriate peer-review process.

Objectivity

Articles that are submitted to the journal are always evaluated without any prejudice.

Confidentiality

The editor must not disclose any information about a submitted article to anyone other than editorial staff, reviewers, and publisher.

Conflicts of Interest and Disclosure

Cam ve Sakura Medical Journal (CSMJ) does not allow any conflicts of interest between the parties such as authors, reviewers and editors. Unpublished materials in a submitted article must not be used by anyone without the express written assent of the author.

Fundamental Errors in Published Works

Authors are obliged to notify the journal's editors or publisher immediately and to cooperate with them to correct or retract the article if significant errors or inaccuracies are detected in the published work. If the editors or publisher learn from a third party that a published work contains a material error or inaccuracy, the authors must promptly correct or retract the article or provide the journal editors with evidence of the accuracy of the article.

C. DUTIES OF REVIEWERS:**Evaluation**

Reviewers evaluate manuscripts without origin, gender, sexual orientation or political philosophy of the authors. Reviewers also ensure a fair blind peer review of the submitted manuscripts for evaluation.

Confidentiality

All the information relative to submitted articles is kept confidential. The reviewers must not be discussed with others except if authorized by the editor.

Disclosure and Conflict of Interest

The reviewers have no conflict of interest regarding parties such as authors, funders, editors, etc.

Contribution to editor

Reviewers help the editor in making decisions and may also assist the author in improving the manuscript.

Objectivity

They always do objective judgment evaluation. The reviewers express their views clearly with appropriate supporting arguments.

Acknowledgement of Sources

Reviewers ought to identify a relevant published study that the authors have not cited. Reviewers also call to the editor's attention any substantial similarity or overlap between the manuscript and any other published paper of which they have personal knowledge.

D. DUTIES OF AUTHORS:**Reporting Standards**

A submitted manuscript should be original, and the authors ensure that the manuscript has never been published previously in any journal. Data of the research ought to be represented literally in the article. A manuscript ought to include adequate detail and references to allow others to replicate the study.

Originality

The authors who want to submit their study to the journal must ensure that their study is entirely original. The words and sentences getting from the literature should be appropriately cited.

Multiple Publications

Authors should not submit the same study for publishing in any other journals. Simultaneous submission of the same study to more than one journal is unacceptable and constitutes unethical behaviour.

Acknowledgement of Sources

Convenient acknowledgement of the study of others has to be given. Authors ought to cite publications that have been efficient in determining the study. All of the sources that used the process of the study should be remarked.

Authorship of a Paper

Authorship of a paper ought to be limited to those who have made a noteworthy contribution to the study. If others have participated in the research, they should be listed as contributors. Authorship also includes a corresponding author who is in communication with the editor of a journal. The corresponding author should ensure that all appropriate co-authors are included in a paper.

Disclosure and Conflicts of Interest

All sources of financial support should be disclosed. All authors ought to disclose a meaningful conflict of interest in the process of forming their study. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board of the Cam ve Sakura Medical Journal (CSMJ). The ICMJE Potential Conflict of Interest Disclosure Form should be filled in and submitted by all contributing authors to disclose a potential conflict of interest. The journal's Editorial Board determines cases of a potential conflict of interest

Peer Review, Publication Ethics and Malpractice Statement

of the editors, authors, or reviewers within the scope of COPE and ICMJE guidelines.

Conditions that provide financial or personal benefit bring about a conflict of interest. The reliability of the scientific process and the published articles is directly related to the objective consideration of conflicts of interest during the planning, implementation, writing, evaluation, editing, and publication of scientific studies.

Financial relations are the most easily identified conflicts of interest, and it is inevitable that they will undermine the credibility of the journal, the authors, and the science. These conflicts can be caused by individual relations, academic competition, or intellectual approaches. The authors should refrain as much as possible from making agreements with sponsors in the opinion of gaining profit or any other advantage that restrict their ability to access all data of the study or analyze, interpret, prepare, and publish their articles. In order to prevent conflicts of interest, editors should refrain from bringing together those who may have any relationship between them during the evaluation of the studies. The editors, who make the final decision about the articles, should not have any personal, professional or financial ties with any of the issues they are going to decide.

Authors should inform the editorial board concerning potential conflicts of interest to ensure that their articles will be evaluated within the framework of ethical principles through an independent assessment process.

If one of the editors is an author in any manuscript, the editor is excluded from the manuscript evaluation process. In order to prevent any conflict of interest, the article evaluation process is carried out as double-blinded. Because of the double-blinded evaluation process, except for the Editor-in-Chief, none of the editorial board members, international advisory board members, or reviewers is informed about the authors of the manuscript or institutions of the authors.

Our publication team works devotedly to ensuring that the evaluation process is conducted impartially, considering all these situations.

The conflict of interest form that each author has to sign must be uploaded during the manuscript submission.

Instructions to Authors

Editorial, Publication and Peer-review Process

The editorial and publication processes of the journal are established in accordance with the international guidelines. The most important criteria of the manuscripts for publication include originality, scientific quality, and citation potential. The authors should guarantee that the manuscripts have not been previously published and/or are under consideration for publication elsewhere. The scientific and ethical liability of the manuscripts belongs to the authors, and the copyright of the manuscripts belongs to CSMJ. Authors are responsible for the contents of the manuscript and the accuracy of the references. All manuscripts submitted for publication must be accompanied by the Copyright Agreement and Authorship Acknowledgement Form. The manuscript should be submitted when this form has been signed by all the authors. By the submission of this form, it is understood that neither the manuscript nor the data it contains have been submitted elsewhere or previously published, and authors declare the statement of scientific contributions and responsibilities of all authors.

Manuscripts submitted to the CSMJ will be evaluated by a double-blind peer-review process. Each submission will be reviewed by the chief editor, deputy and associate editors and at least two external, independent peer expert reviewers. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The reviewers will be requested to complete the review process within 6-8 weeks. Authors will be informed within a period of 8 weeks about the process. Upon review, those manuscripts, which are accepted, shall be published in the journal and issued on <http://www.csmedj.org>.

CSMJ does not charge any article submission or processing charges.

General Guidelines

Manuscripts can only be submitted electronically through the Manuscript Manager website (csmedj.manuscriptmanager.net) after creating an account. This system allows online submission and review.

Format: Manuscripts should be prepared using Microsoft Word, size A4 with 2.5 cm margins on all sides, 12 pt Arial font and 1.5 line spacing.

Abbreviations: Abbreviations should be defined at first mention and used consistently thereafter. Internationally accepted abbreviations should be used; refer to scientific writing guides as necessary.

Cover letter: The cover letter should include statements about the manuscript type, single-journal submission affirmation, conflict of interest statement, sources of outside funding, equipment (if applicable), approval of language for articles in English and approval of statistical analysis for original research articles.

The Editorial Policies and General Guidelines for manuscript preparation specified below are based on "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2016, archived at <http://www.icmje.org/>).

Preparation of research articles, systematic reviews and meta-analyses must comply with study design guidelines:

CONSORT statement for randomized controlled trials (Moher D, Schultz KF, Altman D, for the CONSORT Group. The CONSORT statement

revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA* 2001; 285:1987-91) (<http://www.consort-statement.org/>);

PRISMA statement of preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 2009; 6(7): e1000097.) (<http://www.prisma-statement.org/>);

STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al., for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *Ann Intern Med* 2003;138:40-4.) (<http://www.stard-statement.org/>);

STROBE statement, a checklist of items that should be included in reports of observational studies (<http://www.strobe-statement.org/>);

MOOSE guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; 283: 2008-12).

Manuscripts are accepted only online and can be submitted electronically through web site (<http://csmedj.org>) after creating an account. This system allows online submission and review. The ORCID (Open Researcher and Contributor ID) number of the correspondence author should be provided while sending the manuscript. A free registration can be done at <http://orcid.org>. The manuscripts gathered with this system are archived according to ICMJE-www.icmje.org, Index Medicus (Medline/PubMed) and Ulakbim-Turkish Medicine Index Rules. Rejected manuscripts, except artworks, are not returned.

All pages of the manuscript should be numbered at the top right-hand corner, except for the title page. Papers should include the necessary number of tables and figures in order to provide a better understanding. The rules for the title page, references, figures and tables are valid for all types of articles published in this journal. Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal's guidelines. Submissions that do not conform to the journal's guidelines will be returned to the submitting author with technical correction requests.

Ethical Guidelines

An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects," amended in October 20, www.wma.net) is required for experimental, clinical, and drug studies. Information about patient consent, the name and approval number of the ethics committee should be stated in the manuscript. Submissions that do not have ethical approval will be rejected after editorial review due to the lack of approval.

For experimental studies performed on animals, approval of research protocols by the Ethics Committee in accordance with international agreements is required. Also, a statement including measures for the

prevention of pain and suffering should be declared in the manuscript. For manuscripts concerning experimental research on humans, a statement should be included that written informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo. The authors have the responsibility to protect the patients' anonymity carefully. For photographs that may reveal the identity of the patients, signed releases of the patient or their legal representative should be obtained, and publication approval must be provided in the manuscript. Authors must provide disclosure/acknowledgement of financial or material support, if any was received, for the submitted study. If the article includes any direct or indirect commercial links or if any institution provided material support to the study, authors must state in the cover letter that they have no relationship with the commercial product, drug, a pharmaceutical company. Concerned; or specify the type of relationship. Authors must provide a conflict of interest statement and an authorship contribution form.

The scientific board guiding the selection of the papers to be published in the Journal consists of elected experts of the Journal, and if necessary, selected from national and international authorities. The Editor-in-Chief, Associate Editors, biostatistics expert and language editors may make minor corrections to accepted manuscripts that do not change the main text of the paper.

Plagiarism and Ethical Misconduct

Cam & Sakura Medical Journal is sensitive about plagiarism. All submissions are screened by a similarity detection software (iThenticate by CrossCheck) at any point during the peer-review and/or production process. Authors are strongly recommended to avoid any form of plagiarism and ethical misconduct for the prevention of acceptance and/or publication processes. Results indicating plagiarism may result in manuscripts being returned for revision or rejected. In case of any suspicion or claim regarding scientific shortcomings or ethical infringement, the journal reserves the right to submit the manuscript to the supporting institutions or other authorities for investigation. CSMJ accepts the responsibility of initiating action but does not undertake any responsibility for an actual investigation or any power of decision.

Statistics

Every submission that contains statistical analyses or data-processing steps must explain the statistical methods in a detailed manner, either in the Methods or the relevant figure legend. Any special statistical code or software needed for scientists to reuse or reanalyse datasets should be discussed. We encourage authors to make openly available any code or scripts that would help readers reproduce any data-processing steps. Authors are also encouraged to summarize their datasets with descriptive statistics which should include the n value for each dataset; a clearly labelled measure of centre (such as the mean or the median); and a clearly labelled measure of variability (such as standard deviation or range). Ranges are more appropriate than standard deviations or standard errors for small datasets. Graphs should include clearly labelled error bars. Authors must state whether a number that follows the \pm sign is a standard error (s.e.m.) or a standard deviation (s.d.). Authors must clearly explain the

independence of any replicate measurements, and 'technical replicates' – repeated measurements on the same sample – should be clearly identified. When hypothesis-based tests must be used, authors should state the name of the statistical test; the n value for each statistical analysis; the comparisons of interest; a justification for the use of that test (including, for example, a discussion of the normality of the data when the test is appropriate only for normal data); the alpha level for all tests, whether the tests were one-tailed or two-tailed; and the actual p-value for each test (not merely 'significant' or 'p < 0.05'). It should be clear what statistical test was used to generate every p-value. Use of the word 'significant' should always be accompanied by a p-value; otherwise, use 'substantial', 'considerable', etc. Multiple test corrections must be used when appropriate and described in detail in the manuscript.

All manuscripts selected for full peer review will be assessed by a statistical editor, and their comments must be addressed in full.

Preparation of the Manuscript

a. Title Page

The title page should include the full title of the manuscript; information about the author(s) including names, affiliations, highest academic degree and ORCID numbers; contact information (address, phone, mail) of the corresponding author. If the content of the paper has been presented before, and if the summary has been published, the time and place of the conference should be denoted on this page. If any grants or other financial support has been given by any institutions or firms for the study, information must be provided by the authors.

For regular article submissions, "What's known on this subject?" and the "What this study adds?" summaries.

This page should include the title of the manuscript, short title, name(s) of the authors and author information. The following descriptions should be stated in the given order:

1. Title of the manuscript (English), as concise and explanatory as possible, including no abbreviations, up to 135 characters
2. Short title (English), up to 60 characters
3. Name(s) and surname(s) of the author(s) (without abbreviations and academic titles) and affiliations
4. Name, address, e-mail, phone and fax number of the corresponding author
5. The place and date of the scientific meeting in which the manuscript was presented and its abstract published in the abstract book, if applicable.
6. The ORCID (Open Researcher and Contributor ID) number of all authors should be provided while sending the manuscript. A free registration can be done at <http://orcid.org>

b. Abstract

The abstract should summarize the manuscript and should not exceed 300 words. The abstract of the original articles consists of subheadings including "Objective, Methods, Results, and Conclusion". Separate abstract sections are not used in the submission of the review articles, case reports, technical reports, diagnostic puzzles, clinical images, and novel articles. The use of abbreviations should be avoided. Any abbreviations used must be taken into consideration independently of the abbreviations used in the text.

Instructions to Authors

c. Keywords

A list of minimum 4, but no more than 6 keywords must follow the abstract. Keywords in English should be consistent with "Medical Subject Headings (MESH)".

d. Original Article

The instructions in general guidelines should be followed. The main headings of the text should include "Introduction, Material and Methods, Results, Discussion, Study Limitations and Conclusion". The introduction should include the rationale and the background of the study. The results of the study should not be discussed in this part. "Materials and methods" section should be presented in sufficient details to permit the repetition of the work. The statistical methods used should be clearly indicated. Results should also be given in detail to allow the reproduction of the study. The Discussion section should provide a correct and thorough interpretation of the results with the relevant literature. The results should not be repeated in the Discussion Part. The references should be directly related to the findings of the authors. Study Limitation should be detailed in the section. The conclusion section should be highlighted and interpreted with the study's new and important findings.

The excessive use of abbreviations is to be avoided. All abbreviations should be defined when first used by placing them in brackets after the full term. Abbreviations made in the abstract and in the text are taken into consideration separately. Abbreviations of the full terms stated in the abstract must be re-abbreviated after the same full term in the text.

Original Articles should be no longer than 3500 words and include no more than 6 tables and 7 or a total of 15 figures and 40 references. The abstract word limit must be 250.

Introduction

The article should begin with a brief introduction stating why the study was undertaken within the context of previous reports.

Materials and Methods

These should be described and referenced in sufficient detail for other investigators to repeat the work. Ethical consent should be included, as stated above.

The name of the ethical committee, approval number should be stated. At the same time, the Ethics Committee Approval Form should be uploaded with the article.

Results

The Results section should briefly present the experimental data in text, tables, and/or figures. Do not compare your observations with that of others in the results section.

Discussion

The Discussion should focus on the interpretation and significance of the findings with concise and objective comments that describe their relation to other work in that area and contain study limitations.

Study Limitations

Limitations of the study should be detailed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.

Conclusion

The conclusion of the study should be highlighted.

e. References

The reference list should be typed on a separate page at the end of the manuscript. Both in-text citations and references must be prepared according to the Vancouver style. Accuracy of reference data is the author's responsibility. While citing publications, preference should be given to the latest, most up-to-date references. The DOI number should be provided for citation of ahead-of-print publication, Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus/MEDLINE/PubMed. All authors should be listed in the presence of six or fewer authors. If there are seven or more authors, the first three authors should be listed, followed by "et al." References should be cited in text, tables, and figures should be cited as open source (,,4) in parenthesis numbers in parentheses. References should be numbered consecutively according to the order in which they first appear in the text. The reference styles for different types of publications are presented as follows:

i) Standard Journal Article

Salminen P, Paajanen H, Rautio T, et al. Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: the APPAC randomized clinical trial. *JAMA* 2015;313:2340-2348.8.

ii) Book

Getzen TE. Health economics: fundamentals of funds. New York: John Wiley & Sons; 1997.

iii) Chapter of a Book

Volpe JJ: Intracranial hemorrhage; in Volpe JJ (ed): *Neurology of the Newborn*, ed 5. Philadelphia, Saunders, 2008, pp 481-588.

Porter RJ, Meldrum BS. Antiepileptic drugs. In: Katzung BG, editor. *Basic and clinical pharmacology*. 6th ed. Norwalk, CN: Appleton and Lange; 1995. p. 361-380.

If more than one editor: editors.

iv) Conference Papers: Bengtsson S, Solheim BG. Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Reinhoff O, editors. *MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics*; 1992 Sep 6-10; Geneva, Switzerland: North-Holland; 1992. p. 1561-1565.

v) Journal on the Internet: Morse SS. Factors in the emergence of infectious disease. *Emerg Infect Dis* [serial online] 1995 1(1):[24 screens]. Available from: URL:<http://www/cdc.gov/ncidoc/EID/eid.htm>. Accessed December 25, 1999.

vi) Thesis: Kaplan SI. Post-hospital home health care: the elderly access and utilization (thesis). St. Louis (MO): Washington Univ; 1995.

f. Tables, Graphics, Figures, Pictures, Video:

All tables, graphics or figures should be numbered consecutively according to their place in the text and a brief descriptive caption should be given. Abbreviations used should be explained further in the figure's legend. The text of tables especially should be easily understandable and should not repeat the data of the main text. Illustrations already published are acceptable if supplied by permission of the authors for publication. Figures should be done professionally, and no grey colors should be used. Authors are responsible for obtaining permission to publish any figures or illustrations that are protected by copyright, including figures published elsewhere and pictures taken by professional photographers. The journal cannot publish images downloaded from the Internet without appropriate permission.

Figures or illustrations should be uploaded separately.

Special Sections**Reviews**

Reviews will be prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed. These authors and subjects will be invited by the journal. All reviews within the scope of the journal will be taken into consideration by the editors; also, the editors may solicit a review related to the scope of the journal from any specialist and experienced authority in the field.

The entire text should not exceed 25 pages (A4, formatted as specified above).

Reviews should be no longer than 5000 words and include no more than 6 tables and 10 or a total of 20 figures and 80 references. The abstract word limit must be 250.

Case Reports

Case reports should present important and rare clinical experiences. It must provide novel and/or rare clinical data or new insights to the literature. Case reports should consist of an unstructured abstract (maximum 150 words) that summarizes the case. They should consist of the following parts: introduction, case report, discussion. Informed consent or signed releases from the patient or legal representative should be obtained and stated in the manuscript.

Reviews should be no longer than 1000 words and include no more than 200 tables and 10 or a total of 20 figures and 15 references. The abstract word limit must be 150.

Clinical Images

The journal publishes original, interesting, and high quality clinical images having a brief explanation (maximum 500 words excluding references but including figure legends) and of educational significance. It can be signed by no more than 5 authors and can have no more than 5 references and 1 figure or table. Any information that might identify the patient or hospital, including the date, should be removed from the image. An abstract is not

required with this type of manuscripts. The main text of clinical images should be structured with the following subheadings: Case, and References.

Video Article

Video articles should include a brief introduction on case, surgery technique or a content of the video material. The main text should not exceed 500 words. References are welcomed and should not be more than 5. Along with the main document, video material and 3 images should be uploaded during submission. Video format must be mp4 and its size should not exceed 100 MB and be up to 10 minutes. Author should select 3 images, as highlights of the video, and provide them with appropriate explanations. Video and images must be cited within main text.

Technical reports

Technical reports are formal reports designed to convey technical information in a clear and easily accessible format. A technical report should describe the process, progress, or results of technical or scientific research or the state of a technical or scientific research problem. It might also include recommendations and conclusions of the research. Technical reports must include the following sections: abstract, introduction, technical report, discussion, conclusions, references. Technical reports should contain less than 20 references.

Diagnostic puzzle

Diagnostic puzzles report unusual cases that make an educational point. Since the aim of these articles is to stimulate the reader to think about the case, the title should be ambiguous and not give away the final diagnosis immediately. Diagnostic puzzles should include an introduction and answer part. The introduction part should include a brief clinical introduction to a case (maximum 250 words) followed by an image and a question designed to stimulate the reader to think about what the image shows. The legend should not indicate the diagnosis but should simply describe the nature of the image. Then, the answer part should appear later (maximum 250 words) outlines a brief description of the key diagnostic features of the image, the outcome, and a teaching point.

Diagnostic puzzles will not include more than 5 references. The quality of the image must be at least 300dpi and in TIFF, JPEG, GIF or EPS format. Videos are also welcome and should be in .mov, .avi, or .mpeg format.

Novel insight

This section will offer an opportunity for articles instead of the traditional category of Case Reports. Submissions to this section should contribute significant new insights into syndromological problems, molecular approach and real novelties on recognized or entirely new genetic syndromes or a new technique. The novel aspect(s) can be in the phenotype and/or genotype, the presentation, and the investigation. Submissions can be based around a single case or serial cases. Manuscripts for this section will go through the usual peer reviewing process. The manuscripts should contain abstract (maximum 150 words), a brief introduction, case report(s) and discussion.

Instructions to Authors

Letters to the Editor

This section welcomes manuscripts that discuss important parts, overlooked aspects, or lacking parts of a previously published article in this journal. In addition, articles on subjects within the scope of the journal that might have an attraction including educative cases, may also be submitted in the form of a "Letter to the Editor." The manuscripts for this section should be written in an unstructured text including references. The editor may request responses to the letters. There are no separate sections in the text.

Letter to the editors should be no longer than 500 words.

Revision Process

During the submission of the revised version of a manuscript, the authors should submit a detailed "Response to the reviewers and editors" that

states point by point how each issue raised by the reviewers and/or editors has been replied to and where it can be found (each reviewer's comment, followed by the author's reply and line numbers where the changes have been made) as well as an annotated copy of the main document. Revised manuscripts should be submitted within 30 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be cancelled.

Accepted manuscripts are copy-edited for grammar, punctuation, and format. Once the publication process of a manuscript is completed, it is published online on the journal's webpage as an ahead-of-print publication before it is included in its scheduled issue.

LIMITATION TABLE					
Type of Manuscript	Word Limit	Abstract Word Limit	Reference Limit	Table Limit	Figure Limit
Original Article	3500	250 (Structured)	40	6	7 or total of 15 images
Review	5000	250	60	6	10 or total of 20 images
Case Report	1000	150	20	200	10 or total of 20 images
Letter to the Editor	500	No Abstract		No tables	No media
Video Article	500		5		
Diagnostic Puzzle	250 (as a brief clinical introduction)		5		
Clinical Images	500 (as a brief explanation)		5	1	1
Technical Reports			20		

REVIEW

- P1** **Long-COVID, is a New Syndrome?**
Özlem Alıcı

ORIGINAL ARTICLES

- P6** **Reliability and Validity Study of the Turkish Version of the Brief Social Anxiety-Acceptance and Action Questionnaire**
Furkan Bahadır Alptekin, Hüseyin Şehit Burhan, Tacettin Kuru
- P12** **Impact of Nutritional Status on Prognosis in Non-critically ill Patients with COVID-19 Pneumonia**
Ayşe Bahadır, Birsen Pınar Yıldız, Hasan Akın, Arzu Deniz Aksan, Cihan Aydın
- P19** **The Health Literacy and Health-seeking Behavior of Patients with a Chronic Disease Requiring Hospitalization**
Füsün Afşar, Asibe Özkan
- P27** **Rhinitis: A Risk Factor in Asthma Control?**
Cihan Aydın, Nermin Zerman

CASE REPORTS

- P32** **Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine**
Ahmet Can Topçu, Abdurrahman Ekinci, Nihan Kayalar, Mehmed Yanartaş
- P35** **Functional Magnetic Imaging in a Case of Congenital Mirror Movement**
Nilay Taşdemir Hasanbaş, Vasfiye Kabeoğlu, Ayça Altınkaya, Murat Çabalar

Editorial

Dear Colleagues,

It is a great pleasure for us to publish the first issue of Cam & Sakura Medical Journal (CSMJ) in 2023.

In this issue of CSMJ, you can read the review about long COVID and you will try to find the answer if it is a new syndrome or not. As millions of people all over the world had COVID-19 infection, it will be reasonable to know clinical features of long COVID-19 as a new clinical situation. The brief social anxiety-acceptance and action questionnaire (B-SA-AAQ) has been used to evaluate psychological inflexibility in social anxiety. In this issue, you can read the study which evaluated the reliability and validity of Turkish adaption of the B-SA-AAQ. You can also access to the study that reported the use of nutritional risk screening-2002 (NRS-2002) tool for evaluation of nutritional risk in patients with COVID-19 pneumonia. Social anxiety disorder is a psychiatric condition in which there is an intense fear of social situations such as social interactions and performing in front of others. Health literacy can be defined as the ability of an individual to obtain and translate knowledge and information in order to maintain and improve health in a way that is appropriate both for the individual and healthy system. Therefore, the individual can obtain, understand, evaluate and apply correct health information for a disability-free life and to be able to maintain quality of life in sickness and in health throughout lifetime. An original article in this issue evaluates the relationship between health literacy and health-seeking behaviors and the characteristics of patients with a chronic disease requiring hospitalization. The last original study in this issue evaluated the association between rhinitis and asthma control. The possible adverse effects of COVID-19 vaccines have been discussed extensively after the global administration of these vaccines during pandemics. In this issue, you can read the case report that defined concomitant peripheral and pulmonary arterial thromboembolism 35 days after COVID-19 mRNA vaccine. Lastly, you can find the case report that reported the use of functional magnetic imaging in congenital mirror movement patient.

I think you will read these articles with great interest. We are waiting your articles and case reports for future issues.

Hoping to meet you on the second issue of 2023.

On Behalf of Deputy Editors, Associate Editors and Editorial Secretary

Merih Çetinkaya

Editor in Chief

Cam & Sakura Medical Journal



Long-COVID, is a New Syndrome?

Özlem Alici

University of Health Sciences Turkey, Fatih Sultan Mehmet Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, İstanbul, Turkey

ABSTRACT

The ongoing or developing new symptoms after acute coronavirus disease-2019 (COVID-19) infection has emerged as a new clinical problem. This has become a problem facing the globally infected population and health systems. “Long-COVID” can be defined as patients with laboratory-confirmed or clinically present COVID-19 whose symptoms persist for four weeks after diagnosis. Symptoms are remarkably heterogeneous, as seen in acute COVID-19. These symptoms may remain stable or fluctuate. Controversy over its definition complicates accurate diagnosis and management of the disease. The most prominent symptoms were fatigue, sleep disturbances, chest pain, and shortness of breath. Recent reports also highlight the risk of long-term sequelae in those recovering from acute COVID-19, affecting almost all organs such as the skin, respiratory system, cardiovascular system, neuropsychiatric system, and renal system. The long-term effects of COVID-19, in hospitalized and non-hospitalized individuals, across all age groups, should be a priority for future research with standardized and controlled studies.

Keywords: Long-COVID, fatigue, COVID-19, sequelae of COVID-19

Introduction

In the Coronavirus disease-2019 (COVID-19) pandemic, some patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection has developed a wide range of physical and mental health problems four or more weeks after acute infection. These symptoms included a wide range of ongoing or newly emerging symptoms that could not be explained by another diagnosis (1,2). Most people with acute infections recover within a few days to a few weeks after infection, so at least four weeks after infection is considered a baseline from which post-COVID conditions can be identified for the first time. Different terminology are used to describe these long-lasting symptoms, including “long-COVID”, “post-COVID syndrome”, “postacute COVID-19”, “chronic COVID-19”, “post-COVID

conditions”, and “postacute sequelae of SARS-CoV-2 infection”. Whether this set of symptoms represents a new syndrome specific to COVID-19 has yet to be determined (3,4).

Symptoms seen after COVID-19 can occur in different ways (3);

- Persistent symptoms that begin at the time of acute COVID-19 illness,
- New -onset symptoms following an asymptomatic illness or the remission period of acute illness,
- The addition of new symptoms or clinical conditions (e.g., cognitive difficulties) over time, in addition to some persistent symptoms associated with an already existing disease (e.g., shortness of breath),
- Worsening of pre-existing symptoms or conditions.

Address for Correspondence: Assoc. Prof. Özlem Alici MD, University of Health Sciences Turkey, Fatih Sultan Mehmet Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, İstanbul, Turkey

Phone: +90 505 686 00 88 **E-mail:** oalici@gmail.com **ORCID ID:** orcid.org/0000-0003-2901-0707

Received: 03.11.2022 **Accepted:** 08.11.2022



Symptoms

These long-lasting symptoms can occur following both mild and severe acute COVID-19 illness. These symptoms can be categorized under two different headings: physical and psychological symptoms (3,5,6,7,8,9,10).

Physical symptoms can be seen in one-third or more of the patients. Commonly reported physical symptoms include:

- Fatigue
- Cough
- Dyspnea
- Chest pain

Less common are anosmia, arthralgia, headache, rhinitis, dysgeusia, anorexia, dizziness, myalgia, insomnia, alopecia, sweating, decreased libido, and diarrhea.

Psychological and cognitive complaints may occur more frequently than in those recovering from other similar illnesses (8,10,11). It has been reported to be especially common among patients followed up in the intensive care unit (8). The main disorders seen are worsening quality of life, anxiety/depression, and persistent psychological symptoms (5,6,9). In one study, memory impairment was reported in 21% of patients with mild illness and no hospitalization (11).

At least one component of post-intensive care syndrome has been reported in at least three-quarters of COVID-19 survivors (10,12). The most common symptoms of this syndrome are physical weakness (39%), joint stiffness/pain (26%), mental/cognitive dysfunction (26%) and myalgias (21%) (10). Other psychological or cognitive complaints likely to occur are post-traumatic stress disorder, anxiety, depression, and poor memory and concentration.

Symptoms related to post-COVID conditions are summarized below (1,3);

General symptoms

- Fever
- Disturbing fatigue
- Symptoms worsened by physical or mental effort

Respiratory and heart symptoms

- Cough
- Difficulty breathing
- Chest pain
- Heart palpitations

Neurological symptoms

- Headache

- Sleep difficulties
- Difficulty in thinking or concentrating (brain fog)
- Dizziness when standing up
- Depression or anxiety
- Changes in smell or taste

Digestive symptoms

- Diarrhea

Other symptoms

- Arthralgia and myalgia
- Changes in menstrual cycles
- Rash

Among children, although data are limited, the prevalence of persistent symptoms appears lower (1,13). The most commonly reported symptoms were fatigue (3%) and impaired concentration (2%).

The reason why there are such heterogeneous post-COVID conditions may be due to different underlying pathophysiological processes, such as (3);

- Organ damage due to acute phase disease
- Complications from uncontrolled inflammation
- Ongoing viral activity due to a possible in-host viral reservoir
- Inadequate antibody response
- Autoimmunity

Course of Recovery

While most patients with mild acute COVID-19 illness are expected to recover quickly (e.g. two weeks), those with moderate to severe illness may take two to three months, sometimes longer. Another reason for this difference in recovery time may be the underlying premorbid risk factors (14). A longer recovery period is expected in elderly patients with comorbidities, in patients who develop complications during acute illness (e.g. secondary bacterial pneumonia, venous thromboembolism, multisystem inflammatory syndrome) and in patients with prolonged hospitalization or needed intensive care and people who did not obtain COVID-19 vaccine (1,5,8,10,15). It seems that the best way to prevent long COVID-19 in the current situation is not to obtain the disease (1,2).

General Evaluation

There are several guidelines for COVID-19 follow-up after acute illness developed by several organizations

(3,4,16,17,18,19,20). The severity of the previous illness should be taken into account when deciding whether to follow-up the patient. Patients with mild-to-moderate illness that has not required hospitalization do not need to routinely schedule a COVID-19 follow-up visit unless the patient requests one or has progressive or new symptoms. Patients with more severe acute COVID-19 disease who had been hospitalized would be offered a follow-up examination within 2 to 3 weeks at the latest (2). When the patient presents for a follow-up examination, a comprehensive history of COVID-19 should be taken, including the length of hospitalization, complications, treatments given, etc. Physical examination must be performed in detail in patients who have had COVID-19 (3,4,21).

Patients presenting with persistent or increasing respiratory symptoms, fatigue, or weakness should undergo detailed assessment, such as ambulatory pulse-oximetry, in addition to standard vital signs (e.g. blood pressure, heart rate, respiratory rate, pulse-oximetry, body temperature). Orthostatic vital signs may be important for individuals reporting postural symptoms, dizziness, fatigue, cognitive impairment, or weakness (4,21).

The laboratory tests must be ordered on the basis of abnormal tests during the illness and the present symptoms. For most patients recovering from mild acute COVID-19, laboratory testing is not necessary. For patients with ongoing symptoms, it is reasonable to do the basic panel of laboratory tests (2,4,21):

- Complete blood count
- Blood chemistry, including electrolytes and renal function
- Liver function studies, including serum albumin
- Inflammatory markers, C-reactive protein, erythrocyte sedimentation rate, and ferritin

For selected patients:

- Brain natriuretic peptide and troponin, (in patients with heart failure or complicated by myocarditis or with possible cardiac symptoms such as dyspnea, chest discomfort, edema)
- D-dimer (in patients with unexplained persistent or new dyspnea or in any patient with suspected of thromboembolic disease)
- Thyroid function tests in patients with unexplained and persistent fatigue or malaise
- Creatinine kinase in patients with weakness or muscle tenderness

- Antinuclear antibody, rheumatoid factor, anti-cardiolipin, etc. for rheumatological conditions

COVID-19 testing and serology does not need to be routinely retested to establish a diagnosis of post COVID conditions. Serologic testing may be performed for recovering plasma donation or for evaluation of unexplained symptoms in patients with no prior positive COVID-19 serology (2,21).

Management

The primary goal of medical management in these patients is to optimize the quality of life. And these patients should be consulted or referred to relevant specialists for a comprehensive management plan based on their current symptoms and underlying physical and psychiatric conditions (4).

For example; for the following cardiopulmonary problems, the patient would be referred to cardiology or pulmonology if necessary. Ongoing dyspnea, cough, chest discomfort, pleuritic pain, wheezing, orthopnea, chest pain, peripheral edema, palpitations, dizziness, orthostasis, and pre-syncope or syncope are questioned in detail. A comprehensive cardiopulmonary evaluation should be performed based on the basis of their clinical history and findings. Follow-up chest imaging, typically chest radiography at 12 weeks, is recommended for all patients in whom a pulmonary infiltrate or other abnormality is detected on imaging during the acute course of COVID-19. Imaging should be performed without delay, particularly in patients with new or progressive respiratory symptoms. Chest computed tomography (CT) may be preferred if malignancy is suspected, or high-resolution CT may be an appropriate imaging study for patients with suspected interstitial lung disease such as acute respiratory distress syndrome (ARDS). Pulmonary function tests may be a good choice in patients with persistent, progressive, or emerging respiratory symptoms and in patients recovering from ARDS (22,23).

Referral to neurology and psychiatry departments for ongoing or progressive or new neurologic or neurocognitive problems is appropriate. Neurological imaging is typically not recommended unless there is concern for an unexplained neurological deficit or focal lesion or other conditions (4).

It is recommended that all patients be evaluated for signs and symptoms of deep venous thrombosis, pulmonary embolism, or arterial thrombosis (e.g. digital ischemia) in the upper and lower extremities. Patients with documented thromboses are treated similarly to thromboses in non-COVID-19 patients (2).

In addition to these symptoms, note that invasive fungal infections such as rhino-orbital mucormycosis, have been reported in patients recovering from COVID-19. As known, treatment with corticosteroids and poorly controlled diabetes mellitus are the main risk factors for mucormycosis (24,25). In acute COVID-19 patients with these risk factors, mucormycosis should be suspected if sinus congestion, blackish or colorless nasal discharge, facial or eye pain, or visual symptoms are detected following the acute period (26). Other infectious complications have also been observed in COVID-19 patients with these risk factors, including pulmonary aspergillosis (27) and strongyloides hyperinfection (28). Although these infectious complications are generally considered a late complication of acute illness, note that they can also occur late in patients recovering from moderate to severe COVID-19.

Patients with persistent taste and/or olfactory disturbances may benefit from further evaluation and management, and should be referred to an otolaryngologist (2). Adequate

rest, good sleep hygiene, and specific fatigue management strategies may be recommended for patients with persistent fatigue (2).

Additionally, it is good and necessary to be transparent with the patient for the process of goal setting and make it clear that post COVID conditions are not yet well understood, so well as the type, duration, severity, and recovery of post COVID conditions differ among patients.

It would not be wrong to say that the challenging pandemic period we have experienced in the last two years has given us doctors a lot to learn professionally, but considering current knowledge, we can easily say that we still have a long way to go.

Ethics

Peer-review: Externally and internally peer-reviewed.

Financial Disclosure: The author declared that this study received no financial support.

REFERENCES

1. CDC. Long COVID or post-COVID conditions. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Accessed April 22, 2022. <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html>
2. Manaker S, Elmore JG. (2022). COVID-19: Evaluation and management of adults with persistent symptoms following acute illness ("long COVID"). In G. Finlay (Ed.), UpToDate. Retrieved October 29, 2022. from <https://www.uptodate.com/contents/covid-19-evaluation-and-management-of-adults-with-persistent-symptoms-following-acute-illness-long-covid?>
3. Evaluating and Caring for Patients with Post-COVID Conditions: Interim Guidance <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html> (Accessed on June 15, 2021).
4. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. *BMJ* 2020;370:3026.
5. Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. *JAMA* 2020;324:603-605.
6. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect* 2021;27:89-95.
7. Kosugi EM, Lavinsky J, Romano FR, et al. Incomplete and late recovery of sudden olfactory dysfunction in COVID-19. *Braz J Otorhinolaryngol* 2020;86:490-496.
8. Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. *J Med Virol* 2021;93:1013-1022.
9. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. *Eur Respir J* 2020;56:2003276.
10. Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. *JAMA* 2022;327:559-565.
11. Del Brutto OH, Wu S, Mera RM, Costa AF, Recalde BY, Issa NP. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: a longitudinal prospective study nested to a population cohort. *Eur J Neurol* 2021;28:3245-3253.
12. Martillo MA, Dangayach NS, Tabacof L, et al. Postintensive care syndrome in survivors of critical illness related to coronavirus disease 2019: cohort study from a New York City Critical Care Recovery Clinic. *Crit Care Med* 2021;49:1427-1438.
13. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. *JAMA* 2021;326:869-871.
14. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect* 2020;81:4-6.
15. Raghu G, Wilson KC. COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. *Lancet Respir Med* 2020;8:839-842.
16. National Institute for Health and Care Excellence (NICE). NICE COVID-19 rapid guideline: managing the long-term effects of COVID-19. <https://www.nice.org.uk/guidance/ng188> (Accessed on December 21, 2020).
17. Zhao HM, Xie YX, Wang C, et al. Recommendations for respiratory rehabilitation in adults with coronavirus disease 2019. *Chin Med J (Engl)* 2020;133:1595-1602.
18. Barker-Davies RM, O'Sullivan O, Senaratne KPP, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. *Br J Sports Med* 2020;54:949-959.

19. Zeng B, Chen D, Qiu Z, et al. Expert consensus on protocol of rehabilitation for COVID-19 patients using framework and approaches of WHO International Family Classifications. *Aging Med (Milton)* 2020;3:82-94.
20. Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force. *Eur Respir J* 2020;56:2002197.
21. Post-COVID conditions: information for healthcare providers <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html> (Accessed on April 07, 2022).
22. Sardari A, Tabarsi P, Borhany H, Mohiaddin R, Houshmand G. Myocarditis detected after COVID-19 recovery. *Eur Heart J Cardiovasc Imaging* 2021;22:131-132.
23. Ramani C, Davis EM, Kim JS, Provencio JJ, Enfield KB, Kadl A. Post-ICU COVID-19 outcomes: a case series. *Chest* 2021;159:215-218.
24. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. *Mycopathologia* 2020;185:599-606.
25. Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? *Lancet Respir Med* 2021;9:e77.
26. El-Kholy NA, El-Fattah AMA, Khafagy YW. Invasive fungal sinusitis in Post COVID-19 patients: a new clinical entity. *Laryngoscope* 2021;131:2652-2658.
27. Marr KA, Platt A, Tornheim JA, et al. Aspergillosis complicating severe coronavirus disease. *Emerg Infect Dis* 2021;27:18-25.
28. De Wilton A, Nabarro LE, Godbole GS, Chiodini PL, Boyd A, Woods K. Risk of strongyloides hyperinfection syndrome when prescribing dexamethasone in severe COVID-19. *Travel Med Infect Dis* 2021;40:101981.



Reliability and Validity Study of the Turkish Version of the Brief Social Anxiety-Acceptance and Action Questionnaire

✉ Furkan Bahadır Alptekin¹, ✉ Hüseyin Şehit Burhan¹, ✉ Tacettin Kuru²

¹University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, Clinic of Psychiatry, Istanbul, Turkey

²Alanya Alaaddin Keykubat University Training and Research Hospital, Clinic of Psychiatry, Antalya, Turkey

What is known on this subject?

The Brief Social Anxiety-Acceptance and Action Questionnaire (B-SA-AAQ) can measure psychological inflexibility in context of social anxiety.

What this study adds?

Turkish version of the B-SA-AAQ.

ABSTRACT

Objective: Experiential avoidance is closely related to social anxiety, which is a condition characterized by intense fear in social situations, including social interactions and performing in front of others.

Material and Methods: The sample of this study consisted of 113 people. The data were obtained using a demographic form, Brief Social Anxiety-Acceptance and Action Questionnaire (B-SA-AAQ), Acceptance and Action Questionnaire-II (AAQ-II), and hospital anxiety and depression scale (HADS). Internal consistency and item-total correlation were evaluated with Cronbach's alpha coefficient. Confirmatory factor analysis (CFA) was used to test the factor structure. Temporal stability was assessed using the test-retest method.

Results: The Turkish adaptation of the B-SA-AAQ was found to have good internal consistency with a Cronbach's α coefficient of 0.899. CFA indicated a two-factor structure with acceptable fit indices [χ^2 : 22.8, degrees of freedom: 13; root mean square error of approximation (RMSEA): 0.0817; RMSEA 90% confidence interval (CI) lower bond: 0.013, RMSEA 90% CI upper bond: 0.136, CFI: 0.978; Tucker-Lewis index: 0.965]. The B-SA-AAQ and its subscales were significantly correlated with the AAQ-II and HADS ($p < 0.05$). The results of the test-retest correlation analysis indicated temporal stability.

Conclusion: Therefore, the B-SA-AAQ is a reliable and valid scale for measuring experiential avoidance and psychological flexibility in the context of social anxiety.

Keywords: Acceptance and commitment therapy, social phobia, anxiety, depression

Introduction

Social anxiety disorder (SAD) is a prevalent psychiatric condition that affects individuals globally. The defining feature of SAD is an intense fear of social situations, including social interactions and performing in front of others. Individuals with SAD often experience

significant distress when subjected to negative evaluations from others and may cope by avoiding social interactions. Worldwide, lifetime prevalence has been reported between 0.2% and 12.1%. People with SAD rarely get better on their own. Symptoms tend to be persistent and chronic. Additionally, it is often associated with an increased risk



Address for Correspondence: Furkan Bahadır Alptekin MD, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, Clinic of Psychiatry, Istanbul, Turkey

Phone: +90 212 909 60 00 **E-mail:** furkanbahadir0155@gmail.com **ORCID ID:** orcid.org/0000-0002-3844-1800

Received: 13.12.2022 **Accepted:** 22.03.2023

of secondary depression, other anxiety disorders, mood disorders, and impulse control disorders (1,2).

SAD is related to experiential avoidance (3,4). Experiential avoidance refers to a behavioral pattern in which an individual avoids contact specific undesired experiences, including fear-related sensations, thoughts, feelings, memories, and urges to take certain actions. This avoidance behavior is aimed at escaping or evading these psychological events and the situations that trigger them (5). Attempting to escape or avoid a social situation for not experiencing humiliation, social fear, physiological discomfort, and emotional distress may be stated as experiential avoidance related to social phobia. Generalized experiential avoidance may lead to repertoire narrowing (6). Avoidance may act as a barrier to experiencing meaningful social interactions (4). Psychological inflexibility can be defined as the inflexible and rigid prioritization of psychological reactions over chosen values and contingencies when guiding one's actions. This often manifests when individuals try evading or avoid unwanted internal experiences such as thoughts and emotions (7). To put it simply, psychological inflexibility refers to a pattern where an individual's thoughts exert excessive control over their behavior, feelings, and other internal experiences. Alternatively, they may choose to avoid these experiences at the cost of more effective and meaningful actions. These behaviors are believed to play a role in the development, continuation, and worsening of various psychological issues. Both psychological inflexibility and experiential avoidance are thought to contribute to a wide range of mental health problems (8). Numerous studies have been conducted to evaluate the effectiveness of acceptance and commitment therapy, which is rooted in the principles of psychological flexibility, on social anxiety (SA) (9).

Hayes (5) first created the acceptance and action form (AAQ) to assess psychological flexibility/inflexibility. Although it has been widely used for a while, due to low internal consistency, difficulty to understand, and unstable factor structure, a shorter acceptance and action form-II (AAQ-II) was developed (10). This scale is one of the most frequently used scales to evaluate psychological flexibility/inflexibility, which the participant himself filled in.

Experiential avoidance studies show the need for new measures-so AAQ forms for specific contexts or problems (11,12,13). One of them is Social Anxiety-Acceptance and Action Questionnaire (SA-AAQ) (14). Later, MacKenzie et al. (15) developed the short form of SA-AAQ (brief SA-AAQ), aiming to create a scale that can be filled in a shorter time and more easily applied. Using the SA-AAQ as a foundation, researchers

constructed an eight-item, two-factor (acceptance and action) model that included. This model has favorable levels of reliability, as well as convergent, discriminant, and incremental validity. The model also showed a strong positive correlation with the 19-item SA-AAQ in both clinical and non-clinical populations. Cronbach's alpha values of the entire scale, acceptance, and action factors were 0.81, 0.84, and 0.72, respectively (15).

A scale to evaluate the psychological flexibility model, which plays a role in developing and treating anxiety disorders, will provide an essential tool for clinicians and researchers working with SA. Therefore, this study examined the psychometric properties and factor structure of the Turkish adaption of the brief Social Anxiety-Acceptance and Action Questionnaire (B-SA-AAQ) in non-clinical samples. The primary aim of the study was to assess the validity and reliability of the B-SA-AAQ in a Turkish-speaking non-clinical population. Specifically, the study confirms the two-factor structure of the original scale and establish its effectiveness as a tool for measuring experiential avoidance related to SA. A second hypothesis is that experiential avoidance measured by B-SA-AAQ is related to experiential avoidance in general, depression, and anxiety.

Material and Methods

Participants

The individuals, aged 18-65, accepted to participate in the research voluntarily included in this research. The sample consisted of 122 individuals who work in research and training hospital. Nine of 122 participants were identified as outliers by the box plot method, and the data analyzed in the study were collected from 113 individuals.

Procedure

The study was approved by the Ethics Committee of Alaattin Keykubat University (decision no: 11-01, date: 02.11.2022). Before conducting the study, permission was obtained from the developers of the original B-SA-AAQ questionnaire. The Turkish translation of the scale was developed by translating the items into Turkish and then back to English by two bilingual psychiatrists to ensure its accuracy. The Turkish B-SA-AAQ and socio-demographic forms were then administered to the participants. The AAQ-II and hospital anxiety and depression scale (HADS) were also used as measures of psychopathology to investigate the validity of the scale.

Measurement Tools

Demographic Form: The form was developed by researchers and includes questions about age, gender, education, and psychiatric history.

B-SA-AAQ: It was developed to assess the psychological flexibility associated with social phobia by Mackenzie et al. (15). The 7-point Likert-type scale consists of 8 items. The original scale was confirmed using a clinical and a non-clinical sample. Results indicated that an eight-item, two-factor model (acceptance and action) provided a good fit for the B-SA-AAQ in both samples (15).

AAQ-II: It was developed by Bond et al (10). The validity and reliability analyses of the AAQ's new version, which consists of seven items, provided strong statistical evidence across both clinical and non-clinical samples. Furthermore, elevated scores on the scale were found to be indicative of increased levels of psychological inflexibility, leading to a rise in experiential avoidance. The Turkish adaption study of AAQ-II was conducted by Yavuz et al. (16).

HADS: Zigmond and Snaith (17) developed a scale comprising 14 items, of which seven are aimed at assessing anxiety symptoms, and the remaining seven measure depression symptoms. Participants rate the items on a 4-point Likert scale, and scores can range from 0 to 3. The Turkish adaptation of HADS was conducted by Aydemir (18).

Statistical Analysis

For descriptive statistics and psychometric analysis, we used Jamovi version 2.3.21.0. The data underwent tests for univariate and multivariate normality, linearity, and homogeneity of sample variances. Outliers were also checked for. Cronbach's alpha and Pearson's correlation coefficients were used to evaluate internal consistency and item-total correlation. The temporal stability of the Turkish B-SA-AAQ was evaluated by the test-retest correlation, which involved a follow-up assessment a week after the baseline assessment, and then evaluated the results using Pearson's correlation test. To test the two-factor structure obtained from the original form, confirmatory factor analysis (CFA) was used. Their goodness of fit to data can also evaluate the quality of models. Chi-square (χ^2) is very sensitive to sample size; for this reason, relative chi-square was used, which is the chi-square fit index divided by degrees of freedom (χ^2/df), making χ^2 less dependent on sample size. Additionally, also the comparative fit index (CFI), the Tucker-Lewis index (TLI), and the root mean square error of approximation (RMSEA) were used to evaluate the goodness of fit.

Results

Descriptive Statistics

Analyses were conducted with data from 113 people. Seventy-nine were females (69.9%). The mean age was

29.1 (standard deviation: 6.11, range between 18 and 58) (Table 1).

Reliability Analysis

The Cronbach's alpha coefficient was calculated as 0.825 for the internal consistency of the B-SA-AAQ scale with the initial eight items. In the item-total score analysis, the lowest correlation was -0.15 for the 7th (B-SA-AAQ-7) item (Table 2). When the 7th item was deleted, Cronbach's alpha coefficient increased significantly (0.825 to 0.899), and the correlation of this item was significantly lower than other items. For this reason, item 7 has been removed from the scale for ongoing analysis.

For the temporal reliability analysis, 12 participants from the sample refilled B-SA-AAQ one week later the test-retest analysis. Correlation coefficients were calculated by Spearman correlation analysis between 0.824-0.858 for B-SA-AAQ and subscales, and all values were statistically significant ($p < 0.001$). The Cronbach's alpha coefficient was calculated as 0.899 for the internal consistency of the B-SA-AAQ Action subscale 0.774 and 0.865 for the SA-AAQ acceptance subscale.

Construct Validity

CFA was conducted to validate the construct of B-SA-AAQ in Turkish. The CFA of the 7-item structure of B-SA-AAQ was validated and found to have the same two-factor structure as the original B-SA-AAQ in English. Fit indices from the analysis showed good to excellent (χ^2 : 22.8, df: 13; RMSEA: 0.0817; RMSEA 90% CI lower bond: 0.013, RMSEA 90% CI upper bond: 0.136, CFI: 0.978; TLI: 0.965). Additionally, all factor loading values are significant ($p < 0.001$) (Table 3).

Criterion Validity

The relationships between B-SA-AAQ, AAQ-II, and HADS with B-SA-AAQ were evaluated by Pearson correlation analysis for criterion-related validity (Table 4).

Table 1. Socio-demographic variables

Age mean, SD		29.1	6.11
Sex (n, %)	Women	79	69.9
	Men	34	30.1
Education level (n, %)	High school	4	3.6
	University	57	50.4
	Postgraduate	52	46.0
History of psychiatric disorder (n, %)	Yes	33	70.8
	No	80	29.2

n=113, SD: Standard deviation

Discussion

This study aimed to assess the reliability and validity of the Turkish version of B-SA-AAQ, which measures experiential avoidance in SA based on the SA-AAQ. A sample size of at least 5-10 participants per variable was recommended for the analysis of the scale's construct validity. The sample size for this study was 113 individuals who met this criterion. One of the study's hypotheses was that the Turkish version of B-SA-AAQ would preserve the two-factor structure of the original version. CFA was conducted to test this hypothesis, and it showed that B-SA-AAQ has a two-factor structure, with acceptable goodness-of-fit values.

Table 2. Item-total statistics, Cronbach's alpha if item deleted for initial eight items

Item	Cronbach's alpha if item deleted	Corrected item-total correlation
B-SA-AAQ-1	0.785	0.693
B-SA-AAQ-2	0.770	0.776
B-SA-AAQ-3	0.766	0.826
B-SA-AAQ-4	0.791	0.640
B-SA-AAQ-5	0.802	0.572
B-SA-AAQ-6	0.807	0.537
B-SA-AAQ-7	0.899	-0.150
B-SA-AAQ-8	0.780	0.730

B-SA-AAQ: Brief Acceptance and Action Questionnaire for Social Anxiety

The first, third, and fifth items constitute the action subscale, and the second, fourth, sixth, and eighth items constitute the acceptance subscale. The Cronbach's Alpha coefficient was 0.82 for the action subscale, 0.87 for the acceptance subscale, and 0.90 for the total score on the original scale. The study's results indicated adequate internal consistency of the Turkish version of B-SA-AAQ and its subscales. Furthermore, the temporal stability of the scale was assessed through a test-retest reliability analysis conducted one week after the baseline assessment. In test-retest analysis, two scores of B-SA-AAQ at two different times have a strong correlation for all items ($p < 0.001$). This result indicates the temporal stability of B-SA-AAQ and the subscales of B-SA-AAQ.

Pearson's correlation coefficients were used to evaluate the relationships between the action and acceptance subscales, total scores of B-SA-AAQ and the AAQ-II. Given that both scales measure psychological inflexibility and experiential avoidance, it was expected that there would be moderate-to-strong correlations. The results revealed significant correlations ($p < 0.001$) between the total and subscale scores of B-SA-AAQ and AAQ-II, supporting the hypothesis that B-SA-AAQ can measure psychological inflexibility by assessing experiential avoidance. This result provides evidence of convergent validity, and previous studies had similar results (14,15). B-SA-AAQ may have two advantages over AAQ-II. The first is that it makes a context-specific assessment of SA. Tools for measuring experiential avoidance in a specific context can be more sensitive than generic ones such as AAQ-II. The second advantage is that it has a two-factor structure:

Table 3. Model-fit results of confirmatory factor analysis for Turkish B-SA-AAQ

Factor	Item	Estimate	SE	Z	p
Action	B-SA-AAQ-1	1.186	0.138	8.60	<0.001
	B-SA-AAQ-3	0.987	0.144	6.86	<0.001
	B-SA-AAQ-5	1.542	0.144	10.71	<0.001
Acceptance	B-SA-AAQ-2	1.289	0.146	8.84	<0.001
	B-SA-AAQ-4	1.680	0.154	10.93	<0.001
	B-SA-AAQ-6	1.655	0.133	12.40	<0.001
	B-SA-AAQ-8	1.423	0.180	7.92	<0.001

B-SA-AAQ: Brief Acceptance and Action Questionnaire for Social Anxiety, SE: Standard error

Table 4. Pearson Correlation coefficients for criterion-related validity analysis

	B-SA-AAQ-action	B-SA-AAQ-acceptance	B-SA-AAQ -total
AAQ-II	0.520**	0.465**	0.516**
HADS-anxiety	0.315**	0.203*	0.262*
HADS-depression	0.308**	0.255*	0.293*

* $p < 0.05$, ** $p < 0.01$. AAQ-II: Acceptance and action questionnaire-II, HADS: Hospital anxiety and depression scale, B-SA-AAQ: Brief Acceptance and Action Questionnaire for Social Anxiety

acceptance and action. Acceptance refers to the willingness to experience unwanted internal events, and action refers to acting consistently with values.

Psychological inflexibility and experiential avoidance in general and in people with social phobia are correlated with depression and anxiety as hypotheses (15,16). The correlations of HADS, total scores, and subscales of B-SA-AAQ evidenced the convergent validity of B-SA-AAQ. The action subscale of B-SA-AAQ correlates moderately with anxiety and depression subscales of HADS ($r=0.315$, $r=0.308$, $p<0.001$). Additionally, the acceptance subscale ($r=0.203$, $r=0.255$, $p<0.05$) and total scores ($r=0.262$, $r=0.293$, $p<0.05$) of B-SA-AAQ correlate small with the anxiety and depression subscales of HADS. According to these results, despite B-SA-AAQ being developed to assess experiential avoidance related to SA, it can also be a valuable tool for predicting depression and anxiety in general in the context of SA.

The lack of psychological flexibility is considered a critical factor in SAD and leads to the disorder's continuation or persistence and intensification (19). There is a need for easily applicable tools for the rapid assessment of SA and related psychological processes. The abbreviation of the original scale and its translation into Turkish can be helpful in this respect. SA-AAQ has been translated into Korean, Persian, Portuguese, and Thai. However, there is no reliability and validity study for B-SA-AAQ other than the original language. Thus, this may be one of the first versions of B-SA-AAQ other than the original language.

Study Limitations

This study has some limitations that need to be taken into consideration. First, the sample used in the study was non-clinical. Therefore, the results of this study may not be generalized to clinical populations. The primary aim of the study was to provide a Turkish adaptation of the B-SA-AAQ, which offers preliminary evidence for its validity and reliability in the Turkish language. Second, the severity of SA symptoms in the participants was not assessed. Third, due to the cross-sectional design of the study, causal relationships cannot be determined. Future longitudinal studies are needed to explore causal relationships.

Overall, the results of the current result indicated that the B-SA-AAQ is a reliable and valid scale that can measure experiential avoidance. B-SA-AAQ can be an alternative to the AAQ-II and other psychological inflexibility scales for measuring experiential avoidance and psychological inflexibility in people with SA. Furthermore, this scale can be used to tract changes in interventions for managing SA.

Conclusion

In conclusion, the result of the current study stated that the form for the Turkish adaption of the B-SA-AAQ has acceptable reliability and validity, despite some limitations. This measurement tool can examine studies on psychological inflexibility, which has a place in developing and maintaining SA in the national literature and clinical practices. Including this scale in the existing collection of context-specific versions of the AAQ in Turkish can make a valuable contribution to the research on psychological inflexibility and experiential avoidance. Therefore, it may be recommended to support the scale's psychometric properties with samples with different characteristics in the future.

Ethics

Ethics Committee Approval: The study was approved by the Ethics Committee of Alaattin Keykubat University (decision no: 11-01, date: 02.11.2022).

Informed Consent: Participants were instructed on the purpose and design of the study, and informed consent was obtained.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: F.B.A., H.Ş.B., T.K., Concept: F.B.A., Design: F.B.A., H.Ş.B., Data Collection or Processing: H.Ş.B., Analysis or Interpretation: F.B.A., H.Ş.B., Literature Search: F.B.A., T.K., Writing: F.B.A., H.Ş.B., T.K.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

REFERENCES

1. Gkika S, Wittkowski A, Wells A. Social cognition and metacognition in social anxiety: a systematic review. *Clin Psychol Psychother* 2018;25:10-30.
2. Pittelkow MM, Aan Het Rot M, Seidel LJ, Feyer N, Roest AM. Social anxiety and empathy: a systematic review and meta-analysis. *J Anxiety Disord* 2021;78:102357.
3. Khoramnia S, Bavafa A, Jaberghaderi N, et al. The effectiveness of acceptance and commitment therapy for social anxiety disorder: a randomized clinical trial. *Trends Psychiatry Psychother* 2020;42:30-38.
4. Kashdan TB, Goodman FR, Machell KA, et al. A contextual approach to experiential avoidance and social anxiety: evidence from an experimental interaction and daily interactions of people with social anxiety disorder. *Emotion* 2014;14:769-781.
5. Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies - republished article. *Behav Ther* 2016;47:869-885.
6. Ossman WA, Wilson KG, Storaasli RD, McNeill JW. A preliminary investigation of the use of acceptance and commitment therapy in group treatment for social phobia. *Int J Psychol Ter Psychol* 2006;6:397-416.
7. Yavuz F. Acceptance and commitment therapy (ACT): an overview. *Turkiye Klinikleri J Psychiatry* 2015;8:21-27.
8. Levin ME, MacLane C, Daflos S, et al. Examining psychological inflexibility as a transdiagnostic process across psychological disorders. *J Contextual Behav Sci* 2014;3:155-163.
9. Twohig MP, Levin ME. Acceptance and commitment therapy as a treatment for anxiety and depression: a review. *Psychiatr Clin North Am* 2017;40:751-770.
10. Bond FW, Hayes SC, Baer RA, et al. Preliminary psychometric properties of the acceptance and action questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance. *Behav Ther* 2011;42:676-688.
11. Karadere ME, Burhan HS. Turkish version of the forms of responding to self-critical thoughts scale (FoReST): a reliability and validity analysis over non-clinical samples. *Psychiatry and Behavioral Sciences* 2021;11:57-62.
12. Kuru T, Karadere ME, Burhan HS, Safak Y. Reliability and validity study of the Turkish version of the acceptance and action questionnaire for university students. *Psychiatry and Behavioral Sciences* 2021;11:18-24.
13. Aydın G, Aydın Y, Karacan Özdemir N. Work-related acceptance and action questionnaire: reliability and validity study of Turkish version. *Kariyer Psikolojik Danışmanlığı Dergisi* 2020;3:32-54.
14. MacKenzie MB, Kocovski NL. Self-reported acceptance of social anxiety symptoms: development and validation of the social anxiety - acceptance and action questionnaire. *International Journal of Behavioral Consultation and Therapy* 2010;6:214.
15. MacKenzie MB, Kocovski NL, Blackie RA, Carrique LC, Fleming JE, Antony MM. Development of a brief version of the social anxiety – acceptance and action questionnaire. *J Psychopathol Behav Assess* 2017;39:342-354.
16. Yavuz F, Ulusoy S, Iskin M, et al. Turkish version of acceptance and action questionnaire-II (AAQ-II): a reliability and validity analysis in clinical and non-clinical samples. *Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology* 2016;26:397-408.
17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361-370.
18. Aydemir O. Reliability and validity of the Turkish version of hospital anxiety and depression scale. *Turk Psikiyatri Derg* 1997;8:187-280.
19. Azadeh SM, Kazemi-Zahrani H, Besharat MA. Effectiveness of acceptance and commitment therapy on interpersonal problems and psychological flexibility in female high school students with social anxiety disorder. *Glob J Health Sci* 2015;8:131-138.



Impact of Nutritional Status on Prognosis in Non-critically ill Patients with COVID-19 Pneumonia

© Ayşe Bahadır¹, © Birsen Pinar Yıldız², © Hasan Akın¹, © Arzu Deniz Aksan², © Cihan Aydın³

¹University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, Clinic of Chest Diseases, İstanbul, Turkey

²Yedikule Chest Diseases and Thoracic Surgery Research and Training Hospital, Clinic of Chest Diseases, İstanbul, Turkey

³Ahi Evran University Training and Research Hospital, Clinic of Chest Diseases, Kırşehir, Turkey

What is known on this subject?

The current studies have shown that malnourished patients had higher treatment costs and worse prognosis and a longer duration of the hospitalization. Several tools such as nutritional risk screening-2002 (NRS-2002), malnutrition universal screening tool, and mini nutritional assessment-short form (MNA-SF) have been developed and used to assess the nutritional status in hospitalized patients. The NRS-2002, MNA-SF, and the nutritional risk index have been reported to be useful and practical for the NRS-2002 in the coronavirus disease-2019 (COVID-19). The NRS-2002 was found to be more effective than body mass index in predict the prognosis of the COVID-19, especially in elderly patients.

What this study adds?

We suggest that a simple, user-friendly NRS-2002 tool should be performed to evaluate the nutritional risk in COVID-19 pneumonia in routine clinical assessments. Performing NRS-2002 more than once in the hospitalization process may help the physicians in the early treatment of malnutrition and improve the prognosis of the disease.

ABSTRACT

Objective: The study assessed the nutritional status of non-critically ill coronavirus disease-2019 (COVID-19) patients with pneumonia using the nutritional risk screening 2002 (NRS-2002) score and evaluate its impact on prognosis.

Material and Methods: The clinical presentation of COVID-19 disease varies widely from asymptomatic or mild upper respiratory infection to severe life-threatening pneumonia and respiratory failure. Malnutrition negatively affects impair prognosis in COVID-19 patients, but few studies have evaluated the prognostic value of nutritional risk in COVID-19. In this retrospective observational study, non-critically ill COVID-19 patients who were divided into two groups considering their nutritional risk (NRS-2002 score < or ≥3) were compared to each other. Data analysis was performed using SPSS version 22 (Chicago, IL, USA).

Results: A total of 142 non-critically ill patients with COVID-19 were included in the study. The patients with the nutritional risk (NRS-2002 score ≥3) were older and had higher mortality and intensive care unit (ICU) requirement rates than those without the nutritional risk. The groups did not differ regarding gender distribution, body mass index, and length of hospital stay. Compared with survivors, patients who died (n=11, 7.75%) were older and had significantly higher NRS-2002 scores and C-reactive protein levels and lower oxygen saturation and albumin level.

Conclusion: The NRS-2002 test is a practical tool that can help assess the need for ICU admission and mortality in patients with COVID-19 pneumonia. The application of the test early during the disease should be considered for risk assessment, particularly in elderly patients.

Keywords: SARS-CoV, pneumonia, malnutrition, prognosis



Address for Correspondence: Ayşe Bahadır MD, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, Clinic of Chest Diseases, İstanbul, Turkey

Phone: +90 533 365 66 07 **E-mail:** aysebahadir@yahoo.com **ORCID ID:** orcid.org/0000-0002-7006-5550

Received: 15.11.2022 **Accepted:** 16.01.2023

Introduction

Coronavirus disease-2019 (COVID-19) disease is caused by a newly identified type of coronavirus called severe acute respiratory syndrome-coronavirus-2. The virus was first discovered in December 2019, in China and led to a global pandemic that presents with a broad spectrum of clinical manifestations ranging from asymptomatic or mild upper respiratory infection to severe life-threatening pneumonia and respiratory failure. Like almost every viral disease, fever due to acute inflammatory process, anorexia, and subsequent weight loss are common in COVID-19 disease (1).

The first COVID-19 case in Turkey was reported on March 11, 2020 (2). Since then, as in other countries in the world, the number of infected people has increased rapidly. The mortality of the COVID-19 infection was found especially high in elderly patients. Comorbidities such as hypertension, diabetes mellitus (DM), chronic obstructive pulmonary disease, malnutrition, and cancer have been reported as risk factors for the progression of the COVID-19 in the previous studies (3). These studies reported a higher prevalence of DM and malnutrition in older patients with the COVID-19 than in the general population. The results of the studies conducted in Italy and the USA were in contrast with observations from China and those studies pointed out that the severity of COVID-19 was closely related to obesity (4,5). The diagnosis and treatment of malnutrition are crucial for a better prognosis of the COVID-19 disease (6). Malnutrition is a clinic phenomenon that is mostly underdiagnosed and defined simply as imbalanced feeding, under or overfeeding, and affects both thin and obese people (7).

The current studies have shown that malnourished patients had higher treatment costs and worse prognosis and a longer duration of the hospitalization (3). Several tools such as nutritional risk screening (NRS-2002), malnutrition universal screening tool (MUST), and mini nutritional assessment-short form (MNA-SF) have been developed and used to assess the nutritional status in hospitalized patients (3,8). The NRS-2002, MNA-SF, and the nutritional risk index have been reported to be useful and practical for the NRS-2002 in the COVID-19 disease (9). The NRS-2002 was found to be more effective than BMI in predict the prognosis of the COVID-19, especially in older patients (10). To our knowledge, the prognostic value of the nutritional risk in the COVID-19 (disease) was evaluated specifically in several studies, but there is a need for more studies besides the current studies (11). We assess the nutritional status of non-critically ill COVID-19 patients with pneumonia using the NRS-2002 test and evaluate its impact on the prognosis of the disease.

Material and Methods

Subjects

Patients admitted to the hospital and treated with a diagnosis of COVID-19 pneumonia between March 2020 and June 2020 were included in our study. The records of the patients consisting of demographic features, co-morbidities, and laboratory findings were noted. The diagnosis of COVID-19 was reached by polymerase chain reaction (PCR) testing of the oronasal swab for the presence of reminiscent lesions as predominantly peripheral ground-glass opacities at lower lung zones suggesting COVID-19 on chest computed tomography, history of contact with an infected patient, or fever ($>37.3^{\circ}\text{C}$), cough, sputum, or presence of gastrointestinal symptoms, lymphopenia, and ruling out other causes led us to a diagnosis of COVID-19 PCR negative.

The patients and the criteria for hospitalization, infection severity, admission to an intensive care unit (ICU), and discharge were managed according to the Turkish Ministry of Health's COVID-19 management guidelines (2). According to the rules of the Turkish Ministry of Health, evaluation and recording of the nutritional status of all in-patients by the nursing staff using NRS-2002 is mandatory. The first part of NRS-2002 was filled by in-service nurses within the first 24 h of admission; if NRS-2002 score ≥ 3 , the second part is filled by the physicians.

The NRS-2002 were evaluated by asking the following 4 questions:

- Is the body mass index (BMI) $<20.5 \text{ kg/m}^2$?
- Has the patient lost weight within the last week?
- Has the patient had a reduced dietary intake during the last week?
- Is the patient severely ill?

A patient was "not at risk" if BMI is $\geq 20.5 \text{ kg/m}^2$, food intake was normal, the weight has not been declining and the current illness was not severe (i.e., no increased stress metabolism). If at least one of these criteria was met, and the assessment results in by giving a score from 0-3 concerning BMI, recent weight loss, and food intake during the previous weeks. Furthermore, stress metabolism was evaluated with a 0-3 score according to the illness category. Finally, the patients aged 70 years and older get one extra point. Patients with an NRS-2002 score ≥ 3 were accepted as risky nutritionally according to the European Society of Clinical Nutrition and Metabolism (ESPEN) (7). BMI was classified into the following categories: underweight ($<18.5 \text{ kg/m}^2$), healthy weight ($18.5\text{-}24.9 \text{ kg/m}^2$), overweight ($25\text{-}29.9 \text{ kg/m}^2$), and

obesity ≥ 30 kg/m²). Therefore, according to the presence or absence of nutritional risk, our patients were separated into two groups. The demographic features, comorbidity, laboratory findings, length of stay (LOS), and mortality rate in the hospitalization, the requirement of ICU was compared between the two groups. Those under 18 years of age and pregnant were excluded from the study. This study was approved by the University of Health Sciences Turkey, Istanbul Training and Research Hospital Ethical Committee (12.06.2020-2400). The study was performed appropriate to the rules in the Helsinki Declaration.

Statistical Analysis

Continuous variables were presented as mean \pm standard deviation or median (range) and categorical data as percentages as appropriate. Differences between the groups were assessed using a Student's t-test. Categorical data were compared using the χ^2 test: a p value of <0.05 was accepted as significant. The risk factors for mortality were evaluated with cox regression analysis. Results are presented as an odds ratio (OR) with confidence intervals (CI) of 95%. Data analysis was performed using SPSS version 22 (SPSS Inc., Chicago, IL, USA).

Results

A total of 142 COVID-19 patients 82 (57.7%) males and 60 (42.2%) females and the median age was 55 and interquartile range was (42.7-66.2). The minimum age was 21 years, and the maximum was 94 years. The most common associated condition was DM with 31 cases (21.8%). Eleven cases (7.7%) die, and 13 cases (9.2%) required ICU admission. In 59 (41.5%) cases, the PCR test was positive.

The BMI of patients was classified according to the World Health Organization. In the current study, underweight,

normal, overweight, and obese were found in 1.4%, 38.4%, 37.3%, and 23.2% of cases, respectively.

According to NRS-2002, 11 patients (7.7%) had an NRS-2002 score of 3 and over, and were considered as nutritionally at-risk. NRS-2002 score 0:60 (42.3%), score 1:37 (26.1%), score 2:34 (23.9%), score 3:7 (4.9%), score 4:3 (2.1%), and score 6:1 (0.7%).

They were elder and had higher mortality rates, and higher ICU requirement rate than cases with a nutritional risk score of <3 . Four of eleven cases had normal BMI, but the rest of the group were overweight and obese. There was not any statistically significant difference between the albumin levels, BMI, BMI class, length of hospital stays, and gender distribution of these 2 groups (Table 1). The NRS-2002 score of 3 or more was higher in patients aged over 65 than under 65 (17.5% vs. 3.9%, respectively). In other words, the malnutrition risk in the aged ≥ 65 age group was 5 times more than in patients under 65 years of age (OR: 5.1, 95% CI: 1.43-18.8; p value=0.006).

Eleven (7.75%) cases died. Deceased patients were elderly, had significantly higher NRS-2002 scores, and C-reactive protein (CRP), also had lower oxygen saturation and albumin levels than the patients who survived. Gender, BMI, and weight distribution were not different between the groups (Table 2).

The NRS-2002 score was significantly correlated with albumin, age, CRP, oxygen saturation, severity of diseases, LOS, admission to an ICU, and mortality (Table 3).

When the factors affecting the mortality were evaluated with cox regression analysis, albumin and CRP level was found statistically, NRS-2002 test, age, O₂ saturation, and severity of diseases were not found (Table 4).

Table 1. The characteristics of cases with and without nutritional risk according to NRS-2002

	NRS-2002 <3 (n=131)	NRS-2002 ≥ 3 (n=11)	p value
Age (mean)	54.2 \pm 11.4	65.7 \pm 13.5	0.02
LOS (day)	10.2 \pm 5.1	11.8 \pm 13.3.1	0.40
Mortality +/-	5 (3.8%)/126 (96.1%)	6 (54.5%)/5 (45.4%)	0.001
ICU need +/-	4 (3%)/127 (97%)	9 (95.3%)/2 (4.6%)	0.001
Mean of BMI	27.6 \pm 4.5	28.2 \pm 5.9	0.40
Sex M:F	77 (58.7%)/54 (41.2%)	5 (45.4%)/6 (54.5%)	0.39
Albumin (g/L)	41.6 \pm 3.7	36.1 \pm 0.6	0.64
Age 65 (below/above)	98/33 (96.1%-82.5%)	4/7 (3.9%-17.5%)	0.001
Class of BMI			
Healthy (n=56)	52 (39.7%)	4 (36.4%)	0.81
Overweight (n=86)	79 (60.3%)	7 (63.6%)	

LOS: Length of stay, ICU: Intensive care unit, M: Male, F: Female, BMI: Body mass index, NRS: Nutritional risk screening

Discussion

We performed a nutrition risk evaluation with the NRS-2002 test in non-critical COVID-19 patients in our study. 7.7% of patients were found with a nutritional risk. The patients with NRS-2002 score ≥ 3 had an older age and higher mortality and admission to the ICU than NRS-2002 score < 3 .

In our study, DM was found in one of the five patients followed up with the diagnosis of non-critical COVID-19 pneumonia, and obesity was found in one of the three patients. The patients with a normal BMI ve even obese patients had a nutritional risk. The evaluation of the nutritional status of the patients is crucial because malnutrition increases the infection risk (12).

MNA, subjective global ass (SGA), MUST, and NRS-2002 were designed to evaluate the nutritional risk. MUST has been used mostly as a screening test. SGA, MNA, and NRS-2002 were

assessed in hospitalized patients. NRS-2002 test is remarkable with a design to perform easier and faster than other tests. The NRS-2002 test was validated by the ESPEN and suggested for NRS-2002 of hospitalized COVID-19 patients (8,13). Furthermore NRS-2002 was showed as a valid and reliable test in hospitalized patients in a thesis study in our country (14).

In previous studies, although the nutritional risk ratios were found to be lower according to NRS-2002 compared with tests such as MUST and MNA-SF, NRS-2002 was reported to be more effective in predicting the clinical outcomes of the nutritional status of the patients (15).

A nutritional risk for 77-92% was reported in studies which were performed with the NRS-2002 test in COVID-19 pneumonia and those findings were evaluated to be related to the high amount of old patients (16,17). The NRS-2002 test had a high sensitivity and low specificity to predict the LOS and the need of ICU in COVID-19 patients (16).

Table 2. The comparison of mortality and survival of the cases

	Non-survivor (n=11)	Survivor (n=131)	p value
NRS-2002	2.64 \pm 1.7	0.87 \pm 0.9	0.001
Age (mean)	66.4 \pm 13.1	54.2 \pm 16.4	0.01
BMI (mean)	25.5 \pm 5.1	27.2 \pm 4.6	0.23 NS
Sex M:F	8/3	74/57	0.29 NS
Weight	70.3 \pm 12.7	77.3 \pm 15.4	0.14 NS
Median of CRP (mg/L)	164 \pm 102.5	60.9 \pm 65.3	0.001
Age 65 (below/above)	5/6 (4.9%/15.0%)	97/34 (95.1%/85%)	0.04
O ₂ saturation % (room air)	85.0 \pm 6.6	92.8 \pm 3.9	0.001
Mean of albumin (g/L)	28.7 \pm 8.0	39.0 \pm 4.9	0.001
DM +/-	3/8 (27.3%/76.6%)	28/103 (21.4%/ 78.5%)	0.64 NS
Obesity +/-	9/2 (81.8%/18.1%)	70/59 (54.3%/45.6%)	0.07 NS
Severity of diseases +/-	10/1 (32.3/0.9%)	21/110 (67.7/99.1%)	0.000

BMI: Body mass index, CRP: C-reactive protein, NRS: Nutritional risk screening, NS: Non-significant, M: Male, F: Female, DM: Diabetes mellitus

Table 3. The correlation of NRS-2002 score with clinical and laboratory parameters

Variable	Correlation with NRS-2002	p value	
Age	0.401	0.000	S
Albumin	-0.277	0.001	S
BMI	-0.153	0.70	NS
CRP	0.236	0.05	S
O ₂ saturation (air room)	-0.618	0.001	S
Severity of diseases	0.579	0.001	S
LOS (length of stay)	0.200	0.018	S
ICU	-0.590	0.001	S
Mortality	-0.420	0.001	S

S: Significant, NS: Non-significant, BMI: Body mass index, CRP: C-reactive protein, LOS: Length of stay, ICU: Intensive care unit, NRS: Nutritional risk screening

Table 4. The evaluation of factors affecting mortality according to cox regression analysis

Variable	B	SE	Wald	Df	Sig	Exp (β)	95% CI (min-max)	
Albumin	-0.209	0.089	5.50	1	0.019	0.812	0.682	0.966
CRP	0.017	0.008	4.68	1	0.030	1.01	1.00	1.03
Age	0.056	0.118	0.227	1	0.634	1.05	0.839	1.33
Oxygen saturation	-0.033	0.149	0.049	1	0.825	0.968	0.723	1.29
NRS-2002	0.020	1.57	0.000	1	0.990	1.02	0.047	22.12
Severity of diseases	0.045	1.02	0.193	1	0.661	1.57	0.209	11.79

CRP: C-reactive protein, NRS: Nutritional risk screening, CI: Confidence interval, SE: Standard error, Df: Degrees of freedom

In our study, our nutritional risk rate was found to be 7.7%, lower than that reported in the literature. We think that this might be due to the younger average age of our patient group and the fact that the patients were screened for malnutrition with the NRS-2002 test at admission and the test was not repeated during hospitalization.

In a study conducted on 182 patients over 65 years of age with COVID-19 pneumonia, the risk of malnutrition was found to be 27.5% and to be associated with DM, albumin level, and arm circumference measurement (9). In our study, the nutritional risk rate was found to be 17% in the group over 65 years of age and it was 5 times higher than the group under 65 years of age. Higher predisposition to infections due to the increasing malnutrition risk with older age and impaired immune functions is been known.

Furthermore older age was reported as a risk factor in COVID-19 patients in many studies. Factors affecting the prognosis in COVID-19 pneumonia are reported as advanced age, DM and male gender, and obesity (6). The prevalence of obesity in COVID-19 patients varies between 10-75.8% in studies. Obese patients infected with COVID-19 required more ICU admission and longer hospital stay (5). In our study, our DM rate was 21.8% and our obesity rate was 23%. Although the rate of underweight cases was very low, the rate of obesity was compatible with the literature. We found that there was a nutritional risk not only in patients with normal weight but also in obese patients but DM and obesity were not found to be significant in terms of nutritional risk and mortality.

In this study, the average age, need for ICU admission, and mortality in the nutritional risk group were higher than the group without the nutritional risk. The sex, length of hospital stays, and BMI were not different between the two groups. There was no difference between the groups with and without the nutritional risk in terms of the length of the hospitalization stay rates. We think that it might be due to the reasons that COVID-19 pneumonia is an acute disease, the

rapid progression of the patients, and their discharge to ICU or death may have affected the hospitalization days.

In our study, the mean of BMI and weight of the cases were lower in the non-survivor patients than in the survivor group; however, but the difference was not significant statistically. Also, the sex distribution was not different between the dead and alive patients.

NRS-2002 scores of the patients who died were higher than those who survived, their albumin and oxygen saturation levels were lower, and CRP values were higher. Differences between the groups were statistically significant. Serum albumin level alone may sufficiently reflect malnutrition in hospitalized COVID-19 patients, especially in highly vulnerable individuals (13). Serum albumin level and CRP were reported as independent risk factors for mortality in COVID-19 patients, and an odd ratio was found 0.94 and 1.006 respectively (18). In our study, albumin levels were significantly lower in non-survived patients. Hypoalbuminemia was associated with a poor prognosis of COVID-19 (16). Even the mechanism is unclear, hypoalbuminemia was thought to be caused by increased capillary permeability and liver damage because of the cytokine storm (19).

In a study of elderly hospitalized patients in Brazil, NRS-2002 was found to be more effective than MNA and a MUST in predicting mortality, and it was reported as area under the curve (AUC): 0.78 for death (15). In another study, AUC was reported to be 0.86 to predict death for NRS-2002 (20). The prognostic value of NRS-2002 has been investigated in cancer, COPD, and critical illness (21). NRS-2002 was found to be more effective in predicting clinical prognosis and mortality.

Malnutrition was associated with disease progression and ICU need and mortality in hospitalized patients with COVID-19 pneumonia (11,13).

The NRS-2002 score was significantly correlated with albumin, age, CRP, oxygen saturation, severity of diseases, LOS, admission to an ICU, and mortality. Besides the factors affecting the mortality were evaluated with cox regression

analysis and albumin and CRP level were found statistically, NRS-2002 test, age, oxygen saturation, and severity of diseases were not found.

Many risk factors affect their nutritional status. It has been reported that factors such as socio-economic status, daily dietary intake and lifestyle, exposure to viral load, and time of initiation of treatment affect the nutritional status of patients with COVID patients (16). Since we did not evaluate the nutritional habits of the patients before hospitalization, the gastrointestinal tract symptoms due to viral load, and the side effects of the drugs used in our study, we cannot make any implications about the effect on nutritional risk. Nutrition is a dynamic process, and since the NRS-2002 evaluation is made within the first 24 h of hospitalization, we do not know whether a risk develops in the following days in patients who are not at risk, we think that these reasons have affected our results. Our study was conducted during the first wave of the pandemic, and the majority of the patients had mild-to-moderate infection. We think that the NRS-2002 test may have reduced its effectiveness in evaluating the prognosis of patients with COVID-19 pneumonia.

Malnutrition, frequently overlooked, is defined simply as imbalanced feeding, under or over feeding, and affects both thin and obese people. It is commonly seen in hospitalized patients, affects the prognosis adversely, increases both hospital stay and costs (20). Our results showed that the coexistence of advanced age and nutritional risk as a negative prognostic factor was supported by the finding of high nutritional risk and increased mean age in the non-survivor cases. Even our study did not show any association between the NRS-2002 score and mortality and admission to ICU in non-critical COVID-19 pneumonia, the NRS-2002 score was significantly correlated with albumin, age, CRP, oxygen saturation, severity of diseases, LOS, admission to an ICU, and mortality.

The limitations of the study, single-center and retrospective design of the study, limited data about the physical activity and eating habits affecting the nutritional status of the cases, and evaluation of sarcopenia with BMI. Furthermore, nutritional support products were not assessed because they were excluded from the study. Also, due to the sample size of the study, which was relatively small, our findings could not be generalized to all hospitalized patients.

Despite its limitations, we think that the use of NRS-2002, which is a non-invasive method with lower costs to assess the nutritional risk of COVID-19, helps contribute to the prognosis of the disease.

As a conclusion, the results indicated that the use of the NRS-2002 test in cases with COVID-19 pneumonia was very helpful to assess the need for ICU and mortality. It should be the first step to assess risky patients, especially the elderly and those having acute or chronic diseases. Malnutrition seems to be a problem for viral pandemics in the 21st century and after.

In the future, in a viral pandemic, we might confront a problem named two-sided malnutrition, under and overfeeding, which aggravates the severity of the disease. More studies with nutritional support products are needed.

Study Limitations

The limitations of our study were the single-center setting and retrospective study design as well as the absence of data about physical activity and eating habits of patients, which might have affected the nutritional status of the cases and of evaluation for sarcopenia in addition to BMI. Furthermore, we did not collect information about the use of nutritional support products in our study. Because to the relatively small size of our patient population, our findings can not be generalized. Overall, our results showed that NRS-2002 helped predict the need for ICU admission and the risk of mortality in COVID-19 pneumonia, particularly in older patients.

Conclusion

We suggest that a simple, user-friendly NRS-2002 tool should be performed to evaluate the nutritional risk in COVID-19 pneumonia in routine clinical assessments. Performing NRS-2002 more than once in the hospitalization process may help the physicians in the early treatment of malnutrition and improve the prognosis of the disease.

Ethics

Ethics Committee Approval: This study was approved by the University of Health Sciences Turkey, Istanbul Training and Research Hospital Ethical Committee (12.06.2020-2400).

Informed Consent: An informed consent form was signed by each patient included in the study.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: A.B., B.P.Y., Design: A.B., B.P.Y., H.A., C.A., Data Collection or Processing: A.B., B.P.Y., H.A., Analysis or Interpretation: A.B., B.P.Y., A.D.A., C.A., Literature Search: A.D.A., C.A., Writing: A.B., B.P.Y., C.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

REFERENCES

- Chen Q, Zheng Z, Zhang C, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. *Infection* 2020;48:543-551.
- Türkiye Cumhuriyeti Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. COVID-19 Rehberi. COVID-19 Rehb 2020.
- Mercadal-Orfila G, Lluch-Taltavull J, Campillo-Artero C, Torrent-Quetglas M. Association between nutritional risk based on the NRS-2002 test and hospital morbidity and mortality. *Nutr Hosp* 2012;27:1248-1254
- Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity (Silver Spring)* 2020;28:1195-1199
- Moriconi D, Masi S, Rebelos E, et al. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-CoV-2 shedding. *Obes Res Clin Pract* 2020;14:205-209
- James PT, Ali Z, Armitage AE, et al. The role of nutrition in COVID-19 susceptibility and severity of disease: a systematic review. *J Nutr* 2021;151:1854-1878.
- Tappenden KA, Quatrara B, Parkhurst ML, Malone AM, Fanjiang G, Ziegler TR. Critical role of nutrition in improving quality of care: an interdisciplinary call to action to address adult hospital malnutrition. *J Acad Nutr Diet* 2013;113:1219-1237.
- Kondrup J, Rasmussen HH, Hamberg O, Stanga Z; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS-2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr* 2003;22:321-336.
- Li T, Zhang Y, Gong C, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. *Eur J Clin Nutr* 2020;74:871-875.
- Liu G, Zhang S, Mao Z, Wang W, Hu H. Clinical significance of nutritional risk screening for older adult patients with COVID-19. *Eur J Clin Nutr* 2020;74:876-883.
- Ali AM, Kunugi H. Approaches to nutritional screening in patients with coronavirus disease 2019 (COVID-19). *Int J Environ Res Public Health* 2021;18:2772.
- Katona P, Katona-Apte J. The interaction between nutrition and infection. *Clin Infect Dis* 2008;46:1582-1588.
- Abate SM, Chekole YA, Estifanos MB, Abate KH, Kabthamer RH. Prevalence and outcomes of malnutrition among hospitalized COVID-19 patients: a systematic review and meta-analysis. *Clin Nutr ESPEN* 2021;43:174-183.
- Bolayır B. Hospitalize hastalarda nutrisyonel değerlendirme testi NRS-2002'nin (nutritional risk screening-2002) geçerlilik ve güvenilirliğinin değerlendirilmesi. 2014. <http://www.openaccess.hacettepe.edu.tr:8080/xmlui/bitstream/handle/11655/884/c4606c7d-4e20-42dd-adaf-21717e6b69f0.pdf?sequence=1>
- Raslan M, Gonzalez MC, Dias MC, et al. Comparison of nutritional risk screening tools for predicting clinical outcomes in hospitalized patients. *Nutrition* 2010;26:721-726.
- Del Giorno R, Quarenghi M, Stefanelli K, et al. Nutritional risk screening and body composition in COVID-19 patients hospitalized in an internal medicine ward. *Int J Gen Med* 2020;13:1643-1651.
- Pironi L, Simona A, Ravaioli F, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. January 2020.
- Bannaga AS, Tabuso M, Farrugia A, et al. C-reactive protein and albumin association with mortality of hospitalised SARS-CoV-2 patients: a tertiary hospital experience. *Clin Med (Lond)* 2020;20:463-467.
- Alikiaii B, Heidari Z, Fazeli A, et al. Evaluation of the effectiveness of the nutritional risk screening system 2002 (NRS-2002) in COVID-19 patients admitted to the intensive care unit. *Int J Clin Pract* 2021;75:e14934.
- Wang F, Chen W, Bruening KS, Raj S, Larsen DA. Nutrition screening tools and the prediction of clinical outcomes among chinese hospitalized gastrointestinal disease patients. *PLoS One* 2016;11:e0159436.
- Peng H, Chen BB, Tang LL, et al. Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A large-scale cohort study. *Cancer Sci*. 2018;109:1909-1919.



The Health Literacy and Health-seeking Behavior of Patients with a Chronic Disease Requiring Hospitalization

© Füsün Afşar¹, © Asibe Özkan²

¹University of Health Sciences Turkey, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey

²University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey

What is known on this subject?

Health literacy and health-seeking behavior in people with chronic illness.

What this study adds?

In the debate on diving health inequalities, health knowledge (HL) has been conceded by the World Health Organization as a crucial determinant of health and good. Rapid development of coronavirus disease-2019 (COVID-19) into an epidemic has called for people to acquire and apply health information, and acclimatize their geste at a fast pace. HL and health-seeking behaviours should concentrate on; perfecting the quality of health communication that reaches a diversity of populations, especially by perfecting frontline professional chops and support, enabling people to develop transmittable chops in penetrating, understanding, assaying, and applying health information; and icing that precedence is proportionate to need by reaching and engaging the population groups who are disproportionately affected by low HL.

ABSTRACT

Objective: Health literacy is a broad term encompassing how an individual obtains, understands, evaluates and applies correct health information for a disability-free life and to be able to maintain quality of life in sickness and in health throughout their lifetime. The sources of correct information and health literacy are important factors in being able to achieve the successful management of chronic diseases in particular. This study aimed to examine the relationship between health literacy and health-seeking behaviors and the characteristics of patients with a chronic disease requiring hospitalization.

Material and Methods: The study sample was formed of 194 patients, aged >18 years, treated in the internal medicine clinics of training and research hospital in İstanbul between 1 February and March 30, 2022. Data were collected using a questionnaire consisting of 3 sections. In the statistical analysis, IBM SPSS vn. 23.0 software was used.

Results: A significant negative relationship was determined between health literacy and health-seeking behaviors and age and education level of the demographic characteristics ($p<0.05$). Online health-seeking behavior was determined to be lower in patients with cardiac and chest diseases, and health-seeking behavior was seen to be higher on the first hospitalization ($p<0.05$).

Address for Correspondence: Füsün Afşar, Nurse, University of Health Sciences Turkey, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey

Phone: +90 506 307 60 26 **E-mail:** fusun.af@gmail.com **ORCID ID:** orcid.org/0000-0002-4278-5278

Received: 29.11.2022 **Accepted:** 30.12.2022



Conclusion: It can be considered that studies related to the health literacy and health-seeking behaviors of patients with a chronic disease will be an important source for disease management, enabling patients to lead a disability-free life.

Keywords: Health, literacy intervention, seeking behavior, chronic disease

Introduction

Information and education are basic rights of all healthy and sick individuals in society. In this respect, health literacy is a broad term encompassing how an individual obtains, understands, evaluates and applies correct health information for a disability-free life and to be able to maintain quality of life in sickness and in health throughout their lifetime (1). The United States of America Health and Human Services Department have stated that the target for 2030 is that “health literacy occurs when services are provided that will enable easy access to correct health information that can be understood and used, which will affect people’s decisions and actions”. This goal emphasizes the need to focus on both those who transmit information and those who seek information in the effective dissemination of health information (2).

Chronic diseases are diseases that tend to be long-term, originating from a combination of non-contagious genetic, physiological, environmental, and behavioral factors. A lack of information or incorrect information in chronic disease conditions not only limits the efficacy of treatment but also has a negative effect on self-care and quality of life. Patients with chronic diseases seek health information more on subjects related to drug information, nutrition, disease management, and disease preventative activities. Access to this information is usually currently obtained from healthcare professionals through online or traditional routes. Studies in the literature related to health literacy conducted on patients with chronic diseases have consistently stated that e-health interventions for individuals with chronic diseases have a significant effect on increasing patient participation in and self-management of healthcare services (3).

To be able to maintain quality of life and a disability-free life, especially in chronic diseases, information sharing related to health literacy is a two-way process requiring communication skills to know which questions to ask and which information to share, for the information recipient to be able to access and understand the shared information, and to be able to make the right decision related to the information and put it into practice. Therefore, the healthcare provider has the responsibility to transmit accurate information and the patient to be an active participant in care.

From this starting point, healthcare professionals play a crucial part in promoting health knowledge in cases to help them pierce the healthcare system effectively. This includes helping patients to find, understand, and evaluate health information. Healthcare professionals should evaluate the health literacy needs of patients and check the understanding of the patient for communication of sufficient health information (4).

This study aimed to examine the relationship between health literacy and health-seeking behaviors and the demographic and disease-related characteristics of patients with a chronic disease requiring hospitalization.

Material and Methods

Study Universe and Sample

The study universe was formed of patients treated in the internal medicine clinics of training and research hospital in Istanbul between 1 February and March 30, 2022. Repeated hospitalizations were discounted, and from a total of 364 patients, a minimum sample size of 170 patients was determined from the results of the G*Power 3.1 analysis. The study sample consisted of 194 patients aged >18 years who agreed to participate in the study.

Data Collection Tools

A questionnaire of 3 sections was used for data collection purposes in this study. In the first section, the participants were asked questions to elicit personal and disease-related information. The second section of the questionnaire consisted of the health literacy scale, which was tested for validity and reliability in Turkish by Aras and Bayık Temel (5). This scale consists of 25 items in 4 subscales of access to information (1-5), understanding information (6-12), evaluation (13-20), and application/use (21-25) (5). The internal consistency coefficient (Cronbach alpha) of the health literacy scale has been reported to be 0.92. The third section of the questionnaire comprised the health-seeking behaviour scale, which was developed by Kırac and Öztürk (6). This scale consists of 12 items in 3 subscales of online search, traditional search, and professional search (6). The internal consistency coefficient (Cronbach alpha) of the health-seeking behaviour scale has been reported to be 0.83.

Authorization for the study was attained from the Ethics Committee of University of Health Sciences Turkey, Umraniye Training and Research Hospital (decision no: 1741, dated: 11.01.2021). Written informed consent for participation in the study was obtained from all patients.

Statistical Analysis

Data obtained in the study were analyzed statistically using IBM SPSS vn. 23.0 software. Descriptive statistical methods were used with continuous data reported as mean \pm standard deviation values and categorical data as number (n) and percentage (%). The independent samples t-test, variance tests, and correlation analyses were also used.

Results

The demographic characteristics and disease-related information of the patients hospitalized and treated in the internal clinics are shown in Table 1.

The evaluation was made of 194 patients, comprising 99 (51%) females and 95 (49%) males with a mean age of 57.12 ± 15.71 years. Of the total patients, 125 (64.4%) were married, 124 (63.9%) had a primary school level of education, and 75 (38.7%) were not employed. The hospitalization data were examined and it was seen that 70 (36.1%) were hospitalized in the internal medicine clinic, 96 (49.5%) had been diagnosed within the last year, and 74 (38.1%) had been hospitalized once in the last year (Table 2).

The relationships were examined between the demographic characteristics of the patients and the subscales of the Health Literacy Scale.

A negative correlation was determined between age and the subscales, at a level of statistical significance for access to information (-0.286^*) and understanding information (-0.314^*).

The access to information, evaluation, and application points of females were higher than those of males, and the understanding information points of males were higher than those of females, but the differences were not statistically significant. The health literacy subscale points of single patients were lower than those of the patients who were married or divorced, but not at a level of statistical significance.

In the evaluation of education level, the health literacy subscale points of the patients with a high school or further education level were seen to be higher, and in the understanding information subscale, the points of the patients with a primary school level of education (10.31 ± 6.53) were determined to be statistically significantly lower ($p=0.000^*$).

Clerical workers were seen to have high points in the access to information subscale, manual workers had low points in the evaluation subscale, and retired patients had low points in the application subscale. The understanding information subscale points of the unemployed patients (9.76 ± 6.26) were determined to be statistically significantly low ($p=0.000^*$).

Patients hospitalized in the chest diseases clinic were determined to have lower health literacy subscale points than

Table 1. The demographic characteristics and disease-related information of the patients hospitalized and treated in the internal clinics

Age (years)	57.12 (18-91)	SD 15.71	
		N	%
Gender	Female	99	51.0
	Male	95	49.0
Marital status	Married	125	64.4
	Single	59	30.4
	Divorced	10	5.2
Education level	Primary school	124	63.9
	High school	43	22.2
	Further education	27	13.9
Occupation	Unemployed	75	38.7
	Manual worker	27	13.9
	Retired	20	10.3
	Clerical worker	34	17.5
	Self-employed	38	19.6
Clinic in which hospitalized	Internal	70	36.1
	Nephrology/endocrine	28	14.4
	Cardiology	22	11.3
	Onco-hemato	13	6.7
	Chest diseases	26	13.4
	Neurology	20	10.3
	Dermatology	15	7.7
Time since diagnosis	0-1 year	96	49.5
	2-3 years	35	18.0
	4-5 years	22	11.3
	6-7 years	7	3.6
	8 years	34	17.5
Number of hospitalizations in the last year	First hospitalization	35	18.0
	1	74	38.1
	2	47	24.2
	3	22	11.3
	4	8	4.1
	5	8	4.1

SD: Standard deviation

Table 2. The relationships of the demographic characteristics and disease-related information of the patients with the health literacy scale points

Health literacy		Access to information	Understanding information	Evaluation	Application
Age		-0.286*	-0.314*	-0.065	-0.116
Gender	Female	19.16±6.25	11.49±6.85	11.21±4.30	9.04±4.13
	Male	19.13±5.76	13.23±7.18	10.99±3.99	8.85±4.20
	t	0.041	0.97	-1.724	0.09
	p			0.374	0.71
Marital status	Married	19.30±6.33	12.27±7.32	11.34±4.16	8.87±4.41
	Single	18.71±5.20	12.25±6.60	10.66±4.08	8.97±3.73
	Divorced	19.70±6.62	13.80±6.68	10.80±4.49	9.80±3.43
	F	0.239	0.788	0.223	0.801
	p			0.558	0.573
Education level	Primary school	18.40±6.44	10.31±6.53	11.31±4.24	8.81±4.32
	High school	20.49±4.23	16.67±6.78	10.91±3.73	9.23±4.06
	Further education	20.41±5.90	14.78±5.98	10.48±4.35	9.11±3.63
	F	2.670	0.72	17.382	0.000*
	p			0.500	0.608
Occupation	Unemployed	18.44±6.67	9.76±6.26	11.64±4.29	9.23±4.40
	Manual worker	19.22±6.82	12.19±6.87	9.07±4.85	9.04±4.23
	Clerical worker	20.85±3.45	13.70±7.04	11.50±2.65	8.25±4.42
	Retired	19.82±4.32	14.06±6.81	11.24±3.60	7.91±3.04
	Self-employed	18.97±6.33	15.32±7.38	11.16±4.15	9.63±4.31
	F	0.777	0.54	5.339	0.000*
	p			2.036	0.09
Clinic in which hospitalized	Internal	17.43±6.52	24.74±7.95	28.84±9.47	18.81±6.13
	Nephrology/endocrine	17.82±7.50	24.96±8.53	29.36±12.15	19.07±7.76
	Cardiology	18.05±3.84	24.73±2.73	27.86±3.50	19.81±1.59
	Onco-hemato	19.15±5.29	24.85±7.44	31.08±8.29	19.62±5.19
	Chest diseases	16.23±6.38	22.46±8.18	27.42±10.37	18.00±6.25
	Neurology	18.80±7.30	26.60±9.20	30.35±10.38	19.40±7.34
	Dermatology	19.73±6.96	27.13±8.74	31.60±9.97	22.00±3.57
	F	0.698	0.652	0.764	5.83
	p			0.518	0.794
Time since diagnosis	0-1 year	18.79±6.01	26.27±6.78	30.29±8.32	19.79±5.25
	2-3 years	18.54±6.50	24.60±8.48	28.86±10.14	18.06±6.79
	4-5 years	16.41±7.22	22.82±9.48	26.32±11.81	18.50±7.08
	6-7 years	15.86±7.93	23.29±10.50	24.71±10.53	16.14±8.17
	8 years	15.71±6.31	22.74±7.72	28.88±10.38	19.47±5.90
		F	2.048	0.09	1.901
	p			1.220	0.30
Number of hospitalizations in the last year	First hospitalization	20.83±5.63	29.71±5.32	33.94±6.57	21.57±4.54
	1	17.84±6.09	24.41±7.77	28.49±9.22	19.08±5.70
	2	16.74±6.57	23.48±7.77	28.64±9.66	18.55±5.93
	3	15.32±6.96	21.18±8.39	24.86±11.09	17.18±7.58
	4	17.50±7.98	23.25±9.05	27.13±12.09	17.13±6.66
	5	18.25±5.85	27.75±6.23	30.75±10.63	20.00±7.46
	F	2.573	0.03*	4.769	0.00*
	p			3.002	0.012*

* $p < 0.05$

patients in the other internal disease clinics, but the difference was not statistically significant.

When the relationship was examined between health literacy and the time since diagnosis and the number of hospitalizations within the last year, the health literacy subscale points were determined to be higher for those in the first year of diagnosis and in the first hospitalization, but not at a statistically significant level. A statistically significant difference was determined between the first hospitalization and seeking health literacy information (20.83 ± 5.63 , 0.03^*), understanding information (29.71 ± 5.32 , 0.00^*), and evaluation (33.94 ± 6.57 , 0.012^*) (Table 3).

The relationships were examined between the demographic characteristics of the patients and the subscales of the health-seeking behaviour scale.

A statistically significant negative correlation was determined between age and online (-0.363^*), professional (-0.339^*), and traditional (-0.324^*) health-seeking behaviors.

The traditional health-seeking behavior of males and females was seen to be similar, and the online and professional health-seeking behaviors of males were determined to be higher than those of females, but not at a statistically significant level.

According to marital status, the online and professional health-seeking behaviors were determined to be higher than those of the single and married patients, and the traditional health-seeking behavior of married patients was higher, but the differences were not statistically significant.

When education level was evaluated, the online (16.64 ± 6.57 , 0.002^*), professional (23.14 ± 8.41 , 0.000^*), and traditional (27.53 ± 10.26 , 0.007^*) health-seeking behavior points of the patients with a primary school level of education were determined to be statistically significantly low.

No statistically significant difference was determined in the health-seeking behaviors according to occupation, but the points in all subscales were lower in the unemployed group.

The relationships were examined between the clinics in which the patients were hospitalized and the health-seeking behaviors. The online health-seeking behavior points were determined to be the lowest in the patients hospitalized in the cardiology and chest diseases clinics and highest in the dermatology clinic (0.004^*), and the difference was statistically significant. The professional and traditional health-seeking behavior was higher but not statistically significant in the patients hospitalized in the dermatology clinic. No statistically significant difference was determined in health-seeking behavior according to the time since diagnosis and number

of hospitalizations. No direct or inverse increase or decrease was observed proportional to the time since diagnosis or the number of hospitalizations.

Discussion

Health literacy has become more important in the healthcare agenda both in European countries and in Turkey with the understanding of the inclusion of the role and responsibilities in individual health and the healthcare sector, and this has increased interest in the concept of health literacy. In nationwide studies of health literacy in European countries, it has been reported that of 9007 (57.3%) respondents to a health literacy questionnaire, approximately 4 of every 10 respondents had experienced difficulties in accessing, understanding, evaluating, and applying health information (7).

In the Health Literacy Level and Related Factors Research conducted in 2018 by the Ministry of Health General Directorate for Health Development in Turkey, it was reported that 7 of every 10 individuals had a health literacy level that was insufficient or borderline (8).

In many studies on health literacy, as in the current study, a negative relationship has been reported between age and health literacy, and it has been stated that the level of education and socioeconomic status are the most significant determinants of the health literacy level (9). When studies conducted after 2020 were examined, it was seen that in a study in Germany of 2151 participants aged >18 years, the health literacy of those aged ≥ 76 years was low, and a low level of health literacy was associated with a low level of education and low socioeconomic status (10). Similarly, in a study in Vietnam of 300 individuals aged >55 years, a negative correlation was determined between age and health literacy (11).

In studies that have investigated health literacy and education and occupation, a strong correlation has been reported. In a study conducted with 2433 participants, low health literacy was associated with a lower level of education and low socioeconomic status, and individuals who completed further education were found to have a higher probability of a healthy life compared with those with a low level of education, and low socioeconomic status was associated with lower life expectancy and higher morbidity (12,13,14,15,16). In the current study, the level of education and occupation were determined to be positively correlated with health literacy, and with health-seeking behavior. Another study in the literature, which included 423 individuals evaluated health literacy in terms of e-health, and reported that further

Table 3. The relationships of the demographic characteristics and disease-related information of the patients with the health seeking behaviour scale points

		Online health-seeking behavior	Professional health-seeking behavior	Traditional health-seeking behavior
Age		-0.363*	-0.339*	-0.324*
Gender	Female	17.52±6.67	24.67±8.17	29.18±10.03
	Male	18.16±6.19	25.04±7.47	29.08±9.11
	F p	-0.695 0.49	-0.334 0.74	0.071 0.94
Marital status	Married	17.58±6.59	12.27±7.32	11.34±4.16
	Single	18.10±6.10	12.25±6.60	10.66±4.08
	Divorced	19.30±6.75	13.80±6.68	10.80±4.49
	F p	0.403 0.669	0.572 0.565	0.447 0.640
Education level	Primary school	16.64±6.57	23.14±8.41	27.53±10.26
	High school	20.47±4.90	27.65±5.20	32.14±6.45
	Further education	19.11±6.64	28.26±5.98	31.70±8.93
	F p	6.647 0.002*	8.988 0.000*	5.035 0.007*
Occupation	Unemployed	16.37±6.93	23.11±8.51	27.56±10.66
	Manual worker	19.19±6.42	24.96±8.51	29.37±10.28
	Clerical worker	18.50±5.75	27.80±4.53	31.90±6.14
	Retired	18.15±5.91	26.47±6.27	29.50±7.44
	Self-employed	19.11±5.91	25.21±8.00	30.29±9.83
	F p	1.736 0.14	2.078 0.09	1.082 0.37
Clinic in which hospitalized	Internal	10.41±5.84	11.01±4.18	8.47±4.11
	Nephrology/endocrine	14.57±5.52	11.57±4.38	9.68±4.21
	Cardiology	10.27±6.80	11.82±2.32	8.91±4.05
	Onco-hemato	15.62±8.23	10.92±4.05	9.54±3.97
	Chest diseases	11.77±7.76	10.69±4.48	8.23±4.09
	Neurology	14.00±6.46	9.70±4.80	9.15±3.82
	Dermatology	16.20±7.08	12.33±4.20	10.33±5.22
	F p	3.305 0.004*	0.820 0.555	0.751 0.609
Time since diagnosis	0-1 year	12.51±7.04	11.50±3.97	9.00±4.24
	2-3 years	13.60±7.98	10.46±4.46	9.03±4.19
	4-5 years	11.73±6.37	11.09±4.36	8.23±4.01
	6-7 years	13.00±6.35	9.71±4.50	9.71±4.79
	8 years	10.85±6.70	10.94±4.16	9.03±4.04
	F p	0.576 0.58	0.635 0.64	0.232 0.92
Number of hospitalizations in the last year	First hospitalization	13.54±7.13	12.03±4.27	9.46±4.23
	1	11.45±6.89	11.03±3.99	8.43±4.23
	2	13.30±7.19	11.11±4.01	9.96±3.85
	3	12.36±7.29	11.05±4.04	8.82±4.15
	4	9.50±6.21	9.13±5.00	6.75±4.43
	5	12.63±7.67	9.88±5.30	8.13±4.02
	F p	0.499 0.50	0.859 0.51	1.418 0.22

*p<0.05

education, working as a civil servant, and high income had a positive effect on e-health literacy (17,18).

Previous studies conducted with patients have shown that patients with chronic disorders have a lower level of health literacy, and patients with cardiovascular and chest diseases in particular have more problems in understanding health information (19,20,21). Although there was no statistically significant difference between the clinics with respect to health literacy levels in the current study, as only patients in internal disease clinics were included, the health-seeking behavior points of patients hospitalized in the cardiology and chest diseases clinics were found to be low.

Patients with chronic diseases need health literacy beshouldthey need to understand more health information and read prescriptions accurately, and low health literacy is associated with poor control of chronic diseases, presentation at the emergency department, hospitalization, and increased mortality (10,22,23). In the current study, a negative correlation was determined between the health literacy level and the number of hospitalizations in the last year.

Conclusion

Although few, previous studies related to health literacy and chronic diseases have shown a relationship between the

level of health literacy and the presence of a chronic disease, time since diagnosis, and the number of hospitalizations. It can be considered that studies related to the health literacy of patients with a chronic disease will be an important source to be able to provide disease management, quality of life, and a disability-free life.

Ethics

Ethics Committee Approval: Ethics Committee of University of Health Sciences Turkey, Umraniye Training and Research Hospital (decision no: 1741, dated: 11.01.2021).

Informed Consent: Written informed consent for participation in the study was obtained from all patients.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: F.A., A.Ö., Concept: F.A., A.Ö., Design: F.A., A.Ö., Data Collection or Processing: F.A., Analysis or Interpretation: F.A., Literature Search: F.A., A.Ö., Writing: F.A., A.Ö.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

REFERENCES

- Kickbusch I, Pelikan JM, Apfel F, Tsouros AD. Health literacy: the solid facts. Copenhagen: the World Health Organization, regional office for Europe 2013. <https://apps.who.int/iris/handle/10665/326432>
- Ancker JS, Grossman LV, Benda NC. Health literacy 2030: is it time to redefine the term? *J Gen Intern Med* 2020;35:2427-2430.
- Jessup RL, Osborne RH, Beauchamp A, Bourne A, Buchbinder R. Differences in health literacy profiles of patients admitted to a public and a private hospital in Melbourne, Australia. *BMC Health Serv Res* 2018;18:134.
- Voigt-Barbarowicz M, Brütt AL. The agreement between patients' and healthcare professionals' assessment of patients' health literacy-a systematic review. *Int J Environ Res Public Health* 2020;17:2372.
- Aras Z, Bayık Temel A. Evaluation of the validity and reliability of the Turkish form of the health literacy scale. *F.N. Hem Derg* 2017;25:85-94.
- Kıraç R, Öztürk YE. Sağlık arama davranışı: ölçek geliştirme çalışması. *Süleyman Demirel Üniversitesi Vizyoner Dergisi* 2021;12:224-234.
- Svendson MT, Bak CK, Sørensen K, et al. Associations of health literacy with socioeconomic position, health risk behavior, and health status: a large national population-based survey among Danish adults. *BMC Public Health* 2020;20:565.
- <https://sggm.saglik.gov.tr/> (Date of access: 01.04.2022)
- Yakar B, Gömleksiz M, Piriñçi E. Health literacy levels and affecting factors of patients who applied to a university hospital polyclinic. *Euras J Fam Med* 2019;8:27-35.
- Schaeffer D, Berens EM, Vogt D, et al. Health literacy in Germany - findings of a representative follow-up survey. *Dtsch Arztebl Int* 2021;118:723-728.
- Van Hoa H, Giang HT, Vu PT, Van Tuyen D, Khue PM. Factors associated with health literacy among the elderly people in Vietnam. *Biomed Res Int* 2020;2020:3490635.
- Garcia-Codina O, Juvinyà-Canal D, Amil-Bujan P, et al. Determinants of health literacy in the general population: results of the Catalan health survey. *BMC Public Health* 2019;19:1122.
- Jansen T, Rademakers J, Waverijn G, Verheij R, Osborne R, Heijmans M. The role of health literacy in explaining the association between educational attainment and the use of out-of-hours primary care services in chronically ill people: a survey study. *BMC Health Serv Res* 2018;18:394.
- Hickey KT, Masterson Creber RM, Reading M, et al. Low health literacy: Implications for managing cardiac patients in practice. *Nurse Pract* 2018;43:49-55.

15. Svendsen MT, Bak CK, Sørensen K, et al. Associations of health literacy with socioeconomic position, health risk behavior, and health status: a large national population-based survey among Danish adults. *BMC Public Health* 2020;20:565.
16. Tang C, Wu X, Chen X, Pan B, Yang X. Examining income-related inequality in health literacy and health-information seeking among urban population in China. *BMC Public Health* 2019;19:221.
17. Shiferaw KB, Tilahun BC, Endehabtu BF, Gullslett MK, Mengiste SA. E-health literacy and associated factors among chronic patients in a low-income country: a cross-sectional survey. *BMC Med Inform Decis Mak* 2020;20:181.
18. Estacio EV, Whittle R, Protheroe J. The digital divide: Examining socio-demographic factors associated with health literacy, access and use of internet to seek health information. *J Health Psychol* 2019;24:1668-1675.
19. Walters R, Leslie SJ, Polson R, Cusack T, Gorely T. Establishing the efficacy of interventions to improve health literacy and health behaviours: a systematic review. *BMC Public Health* 2020;20:1040.
20. Friis K, Lasgaard M, Osborne RH, Maindal HT. Gaps in understanding health and engagement with healthcare providers across common long-term conditions: a population survey of health literacy in 29,473 Danish citizens. *BMJ Open* 2016;6:e009627.
21. Stollefson M, Paige SR, Alber JM, et al. Association between health literacy, electronic health literacy, disease-specific knowledge, and health-related quality of life among adults with chronic obstructive pulmonary disease: cross-sectional study. *J Med Internet Res* 2019;21:e12165.
22. Larki A, Tahmasebi R, Reisi M. Factors predicting self-care behaviors among low health literacy hypertensive patients based on health belief model in Bushehr district, South of Iran. *Int J Hypertens* 2018;2018:9752736.
23. Friis K, Pedersen MH, Aaby A, Lasgaard M, Maindal HT. Impact of low health literacy on healthcare utilization in individuals with cardiovascular disease, chronic obstructive pulmonary disease, diabetes and mental disorders. A Danish population-based 4-year follow-up study. *Eur J Public Health* 2020;30:866-872.



Rhinitis: A Risk Factor in Asthma Control?

© Cihan Aydın, © Nermin Zerman

Ahi Evran University Training and Research Hospital, Clinic of Chest Diseases, Kırşehir, Turkey

What is known on this subject?

Asthma is strongly linked to allergic rhinitis (AR). AR is a heterogeneous disorder that is characterized by a group of nasal symptoms. Some studies were conducted to show the worsening effect of rhinitis on asthma control, especially in children and in adult patients comparing the asthma control test (ACT) scores.

What this study adds?

We studied this aspect in adult patients with validated assessment tools and by separating the patients into groups defining AR severity according to visual analog scale and asthma control status according to ACT scores.

ABSTRACT

Objective: We studied the risk factor aspect of rhinitis in adult patients with asthma using validated assessment tools and separating the patients into groups defining rhinitis severity according to visual analog scale and asthma control status according to asthma control test (ACT) scores.

Material and Methods: Asthma is a disease that causes coughing, wheezing, and shortness of breath. It is characterized by variable and recurrent symptoms and reversible airflow obstruction. Allergic rhinitis (AR) is a disease characterized by symptoms like sneezing, itching, nasal congestion, and runny nose. Asthma is linked to AR. AR is diagnosed in 70-90% of the patients, and asthma symptoms are observed in 40-50% of the patients who are diagnosed with AR.

Results: Of 114 patients with asthma receiving treatment, 78.9% were female, and 64% had mild rhinitis symptoms. While 12.3% had diabetes mellitus (DM), 30.7% had hypertension (HT), and 14.9% had ischemic heart disease (IHD). Age, sex, DM, HT, IHD, exacerbation, and diagnosis time groups in the last year did not seem to cause a significant difference in ACT scores. The difference between the rhinitis groups in terms of ACT scores was statistically significant ($F= 8.506$, $p=0.004$, partial $\eta^2=0.087$). According to this result, 8.7% of the total variance asthma control could be explained by the severity of AR.

Conclusion: Severe symptoms of rhinitis are associated with asthma control. Therefore, the management of AR should be targeted in patients whose asthma control cannot be optimized.

Keywords: Asthma, allergic rhinitis, symptom control, quality of life

Introduction

Asthma is a chronic respiratory disease affecting children and adults that causes cough, wheezing, and shortness of breath. It presents with variable and recurrent symptoms and reversible airflow obstruction. Asthma is strongly linked to allergic rhinitis (AR) (1,2). AR is a heterogeneous disorder that is characterized by a group of nasal symptoms.

The “one airway, one disease” one airway, concept was first described by Grossman (3) in 1997. The upper respiratory tract consists of the nose, nasal cavity, pharynx, and larynx. The lower respiratory tract is composed of the trachea, bronchi, bronchioles, and alveoli. The embryological status of the lower and upper respiratory tract is the 4th anterior, which consists of a respiratory diverticulum formed in the ventral wall

Address for Correspondence: Cihan Aydın MD, Ahi Evran University Training and Research Hospital, Clinic of Chest Diseases, Kırşehir, Turkey

Phone: +90 386 280 40 37 **E-mail:** dr.cihanaydin@hotmail.com **ORCID ID:** orcid.org/0000-0002-1789-0172

Received: 21.12.2022 **Accepted:** 03.04.2023



of the intestine. Histologically, the trachea is detailed and structurally similar.

It was found that 70-90% of asthma patients were diagnosed with AR, and 40-50% of patients with AR also had asthma symptoms (4,5). The AR and its impact on asthma (ARIA) guidelines recommend targeting the optimal control of asthma and AR simultaneously (6).

The asthma control test (ACT) is an assessment tool for the quality of life and symptom severity of patients with asthma patients (7). The visual analog scale (VAS) can also be used as an assessment tool for the symptom severity of patients with rhinitis (1,8).

Some studies have shown the worsening effect of AR on asthma control, especially in children (1) and in adult patients by comparing ACT scores (2). In this study, we studied this effect in adult patients with validated assessment tools and by separating the patients into groups defining AR severity according to VAS and asthma control status according to ACT scores.

Material and Methods

Patients

Our prospectively designed single-center study was performed in strong consistency with the ethical standards of the World Medical Association's Declaration of Helsinki and was approved by the Ethical Committee of Kirsehir Ahi Evran University Faculty of Medicine (date: 21.12.2021, approval number: 2021-21/205). An informed consent form was signed by each patient included in the study.

We included patients with asthma and rhinitis presenting to pulmonology outpatient clinics between 01.12.2021 and 01.06.2022. The symptoms of rhinitis were questioned for diagnosis. The prick test was not available in our clinics. The inclusion criteria were being diagnosed with asthma and rhinitis, being treated actively, and signing the informed consent form. Patients who did not agree to sign the informed consent form were excluded.

VAS and ACT scores were measured after treatment for 4 weeks the ARIA and Global Initiative for Asthma Strategy guidelines. The demographic data, ACT and VAS scores, asthma control status, and AR severity levels of the patients were recorded. According to ACT scores, 25 points are classified as complete control, 20-24 points are classified as partial control, and 19 or lower scores are classified as uncontrolled asthma. Then, considering the mean scores, the number of attacks in a year was divided into 2 categories, namely "never having an attack" and "having at least one attack".

Asthma Control Test

ACT was used as an assessment tool to evaluate asthma control after a 4-week treatment. Asthma control was evaluated by asking the following five questions that were answered on a scale of 1 to 5:

1) In the past 4 weeks, how frequently did your asthma keep you from getting as much done at work, school, and home?

2) During the past 4 weeks, how often have you had shortness of breath?

3) During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness, or pain) wake you up at night, or earlier than usual in the morning?

4) During the past 4 weeks, how often have you used a rescue inhaler or nebulizer medication (such as albuterol)?

5) How would you rate your asthma control during the past 4 weeks?

The validity and reliability of ACT were demonstrated by Schatz et al. (7).

Visual Analog Scale

VAS was a tool for evaluate the severity of AR symptoms. AR symptoms were evaluated on a scale of 0 to 10. The validity and reliability of VAS were tested and confirmed by Ciprandi et al. (9) VAS scores of 0-3 indicate mild rhinitis, while scores of 4-7 indicate moderate rhinitis, and scores of 8-10 indicate severe rhinitis.

Statistical Analysis

The sample size required for the study was calculated using the G*Power 3.1.1 program. For this, based on a medium effect size defined by Cohen (1988), which was 0.25 in the analysis of variance, a type I error rate of 0.05, and 80% power, the number of patients to be included was calculated as. One hundred fourteen patients were included in our study.

We analyzed the collected data using the SPSS 25.0 program. Frequency, percentage, mean, standard deviation, and minimum-maximum values were calculated as descriptive statistics. In the study, by calculating the Cronbach's alpha internal consistency coefficient for the total ACT scores and the ACT scores related to AR, sex, age, number of attacks, the duration of diagnosis, and presence of other chronic diseases [diabetes mellitus (DM), hypertension (HT), ischemic heart disease (IHD)] with separate groups (2x2x6x2x2x2x2), eight-way comparisons were made with the mixed-factor analysis of variance (Ten-Way mixed-factor ANOVA) method. In addition,

the interaction effects of asthma control status with the other ten independent variables were examined.

Results

It was determined that 78.9% of the 114 asthma patients were female, and 64% had mild rhinitis. While 12.3% had DM, 30.7% had HT, and 14.9% had IHD. The average age of the patients was 45.55 ± 14.79 , the mean number of asthma attacks in the last year among the patients was 0.17 ± 0.88 , and the mean duration of diagnosis was 6.60 ± 6.30 years (Table 1).

The internal consistency coefficient of ACT was found to be 0.929, while the mean ACT score of the patients was 21.57 ± 3.76 . Considering the GINA steps, which are used to evaluate the severity of asthma, it was seen that the mean asthma severity score of the patients was 2.99 ± 0.36 on a scale of 1 to 5. The patients were asked to evaluate their complaints regarding rhinitis using VAS, and a score between 0 and 10 was used. Because of this evaluation, the mean VAS score of the patients was found to be 1.99 ± 1.91 (Table 2).

In this study, in which the control of asthma was evaluated, First, the total ACT scores of the patients were categorized for the ANOVA as recommended in the literature. The duration of diagnosis was similarly classified as 5 years and shorter and 6 years or longer, which is considered the mean cut-off point. The patients were categorized based on their age groups as 18-24, 25-34, 35-44, 45-54, 55-64, and 65 or older. The Levene's test result was found as $p > 0.05$ ($p = 0.887$) after the conversion of the continuous variables into categorical variables. It was determined that the variances were homogeneously distributed, and the data were then analyzed.

There was a statistically significant difference in the ACT scores between the rhinitis severity groups ($F = 8.506$, $p = 0.004$, partial $\eta^2 = 0.087$). According to this result, 8.7% of the total variance in asthma control could be explained by the severity of AR. The groups formed based on age, sex, DM presence, HT presence, IHD presence, exacerbation in the last year, and the duration of diagnosis did cause a significant difference in the ACT scores of the patients (Table 3).

Table 1. The demographic data

Parameters		n
Gender	Female	90
	Male	24
Allergic rhinitis	Mild	73
	Moderate and severe	41
DM	Yes	14
	No	100
HT	Yes	35
	No	79
IHD	Yes	17
	No	97
Total		114
Age	$\bar{X} \pm SD$: 45.55 ± 14.79	min-max: 18-79
Number of exacerbations in last year	$\bar{X} \pm SD$: 0.17 ± 0.88	min-max: 0-6
The duration of diagnosis (years)	$\bar{X} \pm SD$: 6.60 ± 6.30	min-max: 1-30

DM: Diabetes mellitus, HT: Hypertension, IHD: Ischemic heart disease, \bar{X} : Median, SD: Standard deviation, min: Minimum, max: Maximum

Table 2. Descriptive features of measurement tools

	Min-max	$\bar{X} \pm SD$	Cronbach alpha
ACT	5-25	21.57 ± 3.76	0.929
GINA step	2-5	2.99 ± 0.36	-
VAS	0-7	1.99 ± 1.91	-

ACT: Asthma control test, GINA step: Global initiative for asthma step, VAS: Visual analog scale, \bar{X} : Median, SD: Standard deviation, min: Minimum, max: Maximum

Although there was a statistically significant difference between the ACT scores of the rhinitis severity groups, there was no interaction-common effect of rhinitis severity with other independent variables (Table 3).

Discussion

We showed the worsening impact of rhinitis on asthma control. It can be concluded in general that rhinitis is a risk factor for poor asthma control. Our results were also consistent with the results of previous studies in the literature.

Several studies have shown the relationships between upper respiratory tract pathologies (10,11,12). Type 2 inflammation is a clinical key in pathological processes in asthma and rhinitis cases (13,14). The common inflammatory processes and histological structures lead to a strong link between these diseases, as well as the interaction of asthma control and rhinitis severity.

Emons et al. (1) conducted a study to validate an assessment tool named “CARATkids” in children with asthma and AR symptoms. One hundred and eleven patients were included in their study. Emons et al. (1) also recorded ACT and VAS scores in the next 3 visits of the patients, and they performed Spearman’s correlation analyses. According to their results, it was concluded that AR was a risk factor for poor asthma control, and VAS and ACT scores were significantly correlated.

In a prospectively designed observational study by Linhares et al. (15), similar results were found.

Our study differs from the aforementioned studies in terms of the age of the sample and data analysis methods. The abovementioned studies can contribute to our results on the strong link between asthma and rhinitis.

In a prospective multicenter study by Yasuo et al. (2), 157 patients with asthma were separated into two groups of patients with and those without rhinitis. The GINA steps of the patients in the group with rhinitis were significantly higher. In the group of patients with rhinitis, step 2 asthma rates were lower, and step 4 asthma rates were higher, while there was no statistically significant difference between.

The step 3 asthma rates of the two groups. The female sex was more prevalent than the male sex in both groups.

In this study, the severity of rhinitis was not recorded, but only the diagnosis was evaluated as a parameter and risk factor. Our results were consistent with the findings of Yasuo et al. (2). Furthermore, we separated the patients into groups based on the determination of their asthma control status and rhinitis using ACT and VAS scores. Most of our patients had GINA step 3 asthma, and most patients in our sample were female. The local epidemiological status of asthma and our patient profile were found to be similar. Yasuo et al. (2) also used VAS scores for asthma and found these scores higher in the rhinitis group, which was not a parameter in our study.

Table 3. Eight-way mixed factor analysis of variance in terms of ACT total score

Independent parameters	F	p	Partial η^2
Allergic rhinitis groups (2)	8.506	0.004	0.087
Gender groups (2)	0.372	0.543	0.004
Age groups (6)	0.810	0.546	0.044
DM groups (2)	0.125	0.725	0.001
HT groups (2)	0.006	0.938	0.000
IHD groups (2)	0.620	0.433	0.007
Number of exacerbations groups (2)	0.305	0.582	0.003
Duration of diagnosis groups (2)	0.788	0.377	0.009
Interactions			
Allergic rhinitis groups x gender groups (2x2)	1.157	0.285	0.013
Allergic rhinitis groups x age groups (2x6)	0.800	0.553	0.043
Allergic rhinitis groups x DM groups (2x2)	0.263	0.609	0.003
Allergic rhinitis groups x HT groups (2x2)	0.084	0.773	0.001
Allergic rhinitis groups x IHD groups (2x2)	1.212	0.274	0.013
Allergic rhinitis groups x number of exacerbations groups (2x2)	0.042	0.839	0.000
Allergic rhinitis groups x duration of diagnosis groups (2x2)	1.230	0.270	0.014

DM: Diabetes mellitus, HT: Hypertension, IHD: Ischemic heart disease

Study Limitations

Our results and sample size were consistent with those of the limited number of previous studies in the literature. Our study is remarkable with a better study design including methods such as the creation of patient groups according to asthma control and rhinitis severity.

Conclusion

There was a statistically significant difference in the ACT scores between the rhinitis groups. According to this result, 8.7% of the total variance in asthma control could be explained by the severity of AR. A higher severity of rhinitis was associated with poorer asthma control. Therefore, physicians should target the optimal control of asthma and rhinitis simultaneously.

Ethics

Ethics Committee Approval: Ethical Committee of Kirsehir Ahi Evran University Faculty of Medicine (date: 21.12.2021, approval number: 2021-21/205).

Informed Consent: An informed consent form was signed by each patient included in the study.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: C.A., N.Z., Design: C.A., N.Z., Analysis or Interpretation: C.A., N.Z., Writing: C.A., N.Z.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

REFERENCES

- Emons JA, Flokstra BM, de Jong C, et al. Use of the control of allergic rhinitis and asthma test (CARATkids) in children and adolescents: validation in Dutch. *Pediatr Allergy Immunol* 2017;28:185-190.
- Yasuo M, Kitaguchi Y, Komatsu Y, et al. Self-assessment of allergic rhinitis and asthma (SACRA) questionnaire-based allergic rhinitis treatment improves asthma control in asthmatic patients with allergic rhinitis. *Intern Med* 2017;56:31-39.
- Grossman J. One airway, one disease. *Chest* 1997;111:115-16S.
- Bresciani M, Paradis L, Des Roches A, et al. Rhinosinusitis in severe asthma. *J Allergy Clin Immunol* 2001;107:73-80.
- Terreehorst I, Oosting AJ, Tempels-Pavlica Z, et al. Prevalence and severity of allergic rhinitis in house dust mite-allergic patients with bronchial asthma or atopic dermatitis. *Clin Exp Allergy* 2002;32:1160-1165.
- Bousquet J, Khaltaev N, Cruz A, et al. ARIA update 2008: allergic rhinitis and its effect on asthma. *Allergologie* 2009;32:306-319.
- Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. *J Allergy Clin Immunol* 2006;117:549-556.
- Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. *Clin Exp Allergy* 2013;43:881-888.
- Ciprandi G, Mora F, Cassano M, Gallina AM, Mora R. Visual analog scale (VAS) and nasal obstruction in persistent allergic rhinitis. *Otolaryngol Head Neck Surg* 2009;141:527-529.
- Bianco A, Mazzarella G, Bresciani M, Paciocco G, Spiteri MA. Virus-induced asthma. *Monaldi Arch Chest Dis* 2002;57:188-190.
- Wohlford EM, Borrell LN, Elhawary JR, et al. Differential asthma odds following respiratory infection in children from three minority populations. *PLoS One* 2020;15:e0231782.
- Cardinale F, Lombardi E, Rossi O, Bagnasco D, Bellocchi A, Menzella F. Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. *Expert Rev Respir Med* 2020;14:1019-1026.
- Ritchie AI, Farne HA, Singanayagam A, et al. Pathogenesis of viral infection in exacerbations of airway disease. *Ann Am Thorac Soc* 2015;12:S115-S132.
- Edwards MR, Strong K, Cameron A, Walton RP, Jackson DJ, Johnston SL. Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness. *J Allergy Clin Immunol* 2017;140:909-920.
- Linhares DV, da Fonseca JA, Borrego LM, et al. Validation of control of allergic rhinitis and asthma test for children (CARATKids)-a prospective multicenter study. *Pediatr Allergy Immunol* 2014;25:173-179.



Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine

✉ Ahmet Can Topçu¹, ✉ Abdurrahman Ekinci², ✉ Nihan Kayalar², ✉ Mehmed Yanartaş²

¹Koşuyolu Yüksek İhtisas Training and Research Hospital, Clinic of Cardiovascular Surgery, İstanbul, Turkey

²University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, Clinic of Cardiovascular Surgery, İstanbul, Turkey

What is known on this subject?

Although several European countries reported cases of thromboembolism accompanied by thrombocytopenia following ChAdOx1 (Oxford-AstraZeneca) vaccine, such an association was rarely reported after vaccination with BNT162b2 (Pfizer–BioNTech).

What this study adds?

We present the case of an otherwise healthy patient who developed concomitant acute limb ischemia and extensive pulmonary embolism following the first dose of BNT162b2 vaccine.

ABSTRACT

Although thromboembolism after ChAdOx1 vaccine has been extensively reported, this association was rarely reported after vaccination with BNT162b2. We present the case of an otherwise healthy patient who developed concomitant acute limb ischemia and extensive pulmonary embolism (PE) 35 days after the first dose of BNT162b2 vaccine. Fogarty balloon thrombectomy was performed using open femoral artery exposure, and limb perfusion was restored. Reperfusion strategies were not used for treating PE due to low risk on prognostic assessment. The patient made an uneventful recovery, and she was discharged home on postoperative day 5 on warfarin, and remains symptom-free in a 3-month follow-up. Even though thromboembolic events following BNT162b2 are very rare, concomitant venous and arterial thromboembolism may occur in patients as late as 35 days after vaccination. However, the risk of thromboembolism following BNT162b2 vaccination appears significantly lower compared with severe acute respiratory syndrome-coronavirus-2 infection itself.

Keywords: BNT162b2, coronavirus 2019, vaccination

Introduction

It has been well established that coronavirus disease-2019 (COVID-19), the multi-systemic disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is associated with venous and arterial thromboembolic events across multiple organ systems (1). SARS-CoV-2 vaccines reduce the rate of thromboembolism as they

prevent symptomatic and severe disease (2). Although several European countries reported cases of thromboembolism accompanied by thrombocytopenia following ChAdOx1 (Oxford-AstraZeneca) vaccine, such an association was rarely reported after vaccination with BNT162b2 (Pfizer-BioNTech) (2,3,4). We present the case of an otherwise healthy patient who developed concomitant acute limb ischemia



Address for Correspondence: Ahmet Can Topçu MD, Koşuyolu Yüksek İhtisas Training and Research Hospital, Clinic of Cardiovascular Surgery, İstanbul, Turkey

Phone: +90 216 500 15 00 **E-mail:** ahmet.topcu@icloud.com **ORCID ID:** orcid.org/0000-0002-7335-4788

Received: 12.10.2022 **Accepted:** 23.11.2022

(ALI) and extensive pulmonary embolism (PE) following the first dose of BNT162b2 vaccine.

Case Report

A 62-year-old woman presented with dyspnea and a cold, painful left lower limb. Her medical past was insignificant except for a right total knee replacement that occurred 2 months ago. The patient had recovered from surgery and was already mobile. She had received the first dose of BNT162b2 mRNA vaccine 35 days before presentation. On physical examination, she was slightly tachypneic with normal blood pressure and heart rate. The electrocardiogram showed a sinus rhythm. Heart and lung sounds were normal. Her left lower extremity was cyanotic and cold with absent popliteal and pedal pulses, minimal sensory loss, and normal motor function. Doppler signals distal to the left femoral pulse were inaudible. Laboratory tests revealed normoxia, hypocapnia, a D-dimer level of 5.61 $\mu\text{g/mL}$ (normal range $<0.5 \mu\text{g/mL}$), and a platelet count of 171,000 per μL . Computed tomography angiography of the lower extremities and pulmonary arterial system demonstrated thrombotic occlusion of the left external iliac artery (Figure 1) and bilateral PE (Figure 2). There were not any signs of right ventricular overload or dysfunction, intracardiac thrombi, or any septal defects on the transthoracic echocardiographic examination. Venous duplex ultrasound of the extremities was negative




Figure 1. Three dimensional reconstruction of contrast enhanced computed tomography scan demonstrating left external iliac artery thrombosis

for deep vein thrombosis. A COVID-19 polymerase chain reaction test was also negative. The patient was immediately anticoagulated using unfractionated heparin, and transferred to the operating room for the surgical treatment of ALI. Fogarty balloon thrombectomy was performed using open femoral artery exposure, and limb perfusion was restored. Reperfusion strategies were not used for treating PE due to low risk on prognostic assessment. Genetic thrombophilia testing did not demonstrate an increased risk of thromboembolism. Lupus anticoagulant and anti-cardiolipin antibodies were negative. The patient made an uneventful recovery, and she was discharged home on postoperative day 5 on warfarin, and remains symptom-free in a 3-month follow-up.

Discussion

The current report describes the occurrence of concomitant pulmonary and peripheral arterial thromboembolism following immunization with the BNT162b2 vaccine. There is no direct evidence that thromboembolic events observed in this particular patient were caused by vaccination; however, we failed to demonstrate any other causes of arterial and venous thromboembolism, such as a proximal source or genetic predisposition.

Thromboembolism after ChAdOx1 has been extensively reported, yet such association was rarely reported after BNT162b2 (2,3,4). A recent self-controlled case series study by Hippisley-Cox et al. (5) analyzed over 29 million people in England who received the first doses of ChAdOx1 or BNT162b2 mRNA vaccines and approximately 2 million people with a positive COVID-19 test. The outcomes were hospital admission or death associated with thrombocytopenia or




Figure 2. Contrast enhanced computed tomography scan demonstrating left main pulmonary artery thromboembolism

thromboembolism within 28 days of vaccination or COVID-19 infection. The authors reported that vaccination with ChAdOx1 was associated with increased risks of thrombocytopenia, venous thromboembolism, and rare arterial thromboembolic events. They also reported that vaccination with BNT162b2 increased the risk of arterial thromboembolism, and both vaccines increased the likelihood of cerebral venous sinus thrombosis. However, they also reported that all of the above-mentioned complications were more commonly observed and more prolonged after SARS-CoV-2 infection in the same population (5). Therefore, it can be interpreted that SARS-CoV-2 vaccination protects against thromboembolism during the COVID-19 pandemic.

Another study by Sessa et al. (6) included women ≤ 50 years of age and concluded that mRNA vaccines did not show disproportional reporting of thromboembolic events compared to hormonal contraception. Moreover, others reported that the risk of thromboembolism was not increased 14 days (7), 21 days (8), and 42 days (9) following immunization with BNT162b2. Considering the accumulating evidence, the European Medical Agency has stated that the benefits of vaccination against SARS-CoV-2 continue to outweigh the risk of side effects (10).

Even though thromboembolic events following BNT162b2 are very rare, concomitant venous and arterial thromboembolism may occur in patients as late as 35 days after vaccination. However, the risk of thromboembolism

following BNT162b2 vaccination appears significantly lower compared with SARS-CoV-2 infection itself.

Take home messages

- Thromboembolic events may be rarely be observed following BNT162b2 vaccination.
- The risk of thromboembolism following BNT162b2 vaccination appears significantly lower compared with SARS-CoV-2 infection itself.

Ethics

Informed Consent: Informed consent has been obtained from the patient for publication of the case report and accompanying images.

Peer-review: Internally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: A.C.T., A.E., N.K., M.Y., Concept: A.C.T., A.E., N.K., M.Y., Design: A.C.T., A.E., N.K., M.Y., Data Collection or Processing: A.C.T., A.E., N.K., M.Y., Analysis or Interpretation: A.C.T., A.E., N.K., M.Y., Literature Search: A.C.T., A.E., N.K., M.Y., Writing: A.C.T., A.E., N.K., M.Y.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

REFERENCES

1. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. *EClinicalMedicine* 2020;29:100639.
2. Konstantinides SV. Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us - and what they don't. *Eur Respir J* 2021;58:2101111.
3. Smadja DM, Yue QY, Chocron R, Sanchez O, Lillo-Le Louet A. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. *Eur Respir J* 2021;58:2100956.
4. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021;384:2124-2130.
5. Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. *BMJ* 2021;374:n1931.
6. Sessa M, Kragholm K, Hviid A, Andersen M. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines. *Expert Opin Drug Saf* 2021;20:1451-1453.
7. Jabagi MJ, Botton J, Bertrand M, et al. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older. *JAMA* 2022;327:80-82.
8. Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. *JAMA* 2021;326:1390-1399.
9. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. *N Engl J Med* 2021;385:1078-1090.
10. Franchini M, Liunbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. *Eur J Haematol* 2021;107:173-180.



Functional Magnetic Imaging in a Case of Congenital Mirror Movement

© Nilay Taşdemir Hasanbaş¹, © Vasfiye Kabeloğlu², © Ayça Altinkaya¹, © Murat Çabalar¹

¹University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, Clinic of Neurology, İstanbul, Turkey

²University of Health Sciences Turkey, Bakırköy Prof. Dr. Mazhar Osman Training and Research Hospital, Clinic of Neurology, İstanbul, Turkey

What is known on this subject?

Mirror movements are involuntary movements caused by synchronized mimicry of one side's voluntary muscle movements by the opposite limb's homologous muscles.

What this study adds?

We think that when such complaints are encountered, functional magnetic resonance imaging should primarily be kept in mind and preferred to show the etiopathology non-invasively.

ABSTRACT

Mirror movements are involuntary movements caused by synchronized mimicry of one side's voluntary muscle movements by the opposite limb's homologous muscles. We present a case of mirror movement, which is shown also with functional magnetic resonance imaging.

Keywords: Congenital, EMG, functional MRI, mirror

Introduction

Mirror movements are involuntary movements caused by synchronised mimicry of one side's voluntary muscle movements by opposite limb's homologous muscles. Mirror movements can be seen in all limbs but are mostly seen in the upper limbs, especially in hands (1,2). It is normal to see mirror movements among children before the age of 10 because myelination of corpus callosum has not been finished. Among adults, physiological mirror movements can sometimes be seen due to tiredness, intense physical activity, and age. However, persistence and repetition of these movements are considered abnormal (3,4).

There are two main mechanisms for the formation of mirror movements. The first

one is abnormal tract of ipsilateral motor corticospinal pathway, and the second one is reduced transcallosal inhibition or increased transcallosal excitation. The etiopathology of mirror movements differs by being congenital or acquired (4). Congenital mirror movements can be physiological or pathological. Mild physiological mirror movements of childhood can frequently be seen due to incomplete development of corpus callosum. Congenital mirror movements generally begin in infancy or early childhood. Progression and fluctuations are unlikely. Frequently seen in the upper limbs, especially in the hands and fingers. Cause mild disability. Expected to disappear between ages seven and ten. Pathological mirror movements on the other hand are permanent. Can be seen with isolated or complex congenital syndromes (Kallmann's

Address for Correspondence: Murat Çabalar MD, University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, Clinic of Neurology, İstanbul, Turkey

Phone: +90 212 909 60 00 **E-mail:** mcabalar@gmail.com **ORCID ID:** orcid.org/0000-0002-5301-1067

Received: 09.02.2022 **Accepted:** 29.11.2022



syndrome, Klippel-feil's syndrome, hypoxic ischemic damage, Usher's syndrome, congenital hemiplegia, Friedrich's ataxia) (5,6).

Acquired mirror movements can be seen with many neurodegenerative diseases such as Parkinson's disease and Corticobasal syndrome. Can also accompany stroke, cervico-medullary junction lesions, essential tremor, dystonia, and amyotrophic lateral sclerosis (1,2,4,7,8).

Case Report

Twenty-two-year-old male patient presented with involuntary contractions that were present in one hand while moving the other hand (Video 1). These complaints that were present for the last couple of years and progressing lately were preventing him to work. We found that there was no loss of consciousness and no involvement of the lower limb. And the patient had a normal neurological examination. Pre, peri, and postnatal backgrounds were normal. While being cognitively normal, the patient had slower motor development from the childhood and was also being monitored by endocrinology for hypogonadotropic hypogonadism diagnosis. While being the first of the two children, his parents had first -degree consanguineous marriage and the other child has auditory problems. On physical examination, contractions in the opposite hand were especially evident while making precise motor movements on one hand. Anosmia and hyposmia were absent in the patient. Cranial and cervical magnetic resonance imaging (MRI) were normal (Figure 1). In laboratory examination, routine tests (hemogram and biochemistry), thyroid function tests, vitamins A, E, and B12, selenium,

copper, ceruloplasmin, and lead values were normal. ELISA tests (hepatitis, HIV, HbsAg, anti-Hbs, and HCV) were also negative. In electroneuromyography (EMG) while forearm's voluntary movements, EMG activities in similar muscle groups of the opposite limb were observed. Sensory and motor conduction examinations were normal. In terms of congenital and metabolic anomalies, optometrical and otolaryngological examinations were normal. In functional MRI, it was seen that contralateral cortical motor areas were activated when both, hand actively moved and the other hand contracted involuntarily (Figure 2).

Discussion

Mirror movements are mimicry of the opposite side's voluntary muscle movements, especially in the upper limb distal muscles (3). Among various movement disorders, it is not quite rare. Mirror movements can be problematic. To try to cope with this situation, patients might suppress the mirror movements by contracting the opposite side's antagonist muscles. But even so, mirror movements are disabling. Recognition of these movements is crucial for early diagnosis. Two general mechanisms are suggested for the formation of mirror movements. First: progression of the corticospinal tract of the primary motor cortex (M1) of the hand originating from the same hemisphere to the ipsilateral spinal cord without crossing. These abnormal ipsilateral pathways may be related to the diagonally branching corticospinal fibers. This is thought to be related to the dysfunction of the neural circuits that must operate contralaterally to the primary motor cortex to




Figure 1. Cranial magnetic resonance imaging




Figure 2. (a-c) In functional magnetic resonance imaging, it was seen that contralateral cortical motor areas were activated when both, hand actively moved and the other hand contracted involuntarily

which voluntary movement is dependent. Second: bilateral cortical activation due to decreased transcallosal inhibition or increased transcallosal excitation. As a result, mirror movements occur because of abnormal activation of both hemispheres of single-handed intended movements. The etiopathology of mirror movements provides clues about the congenital or acquired form of the disease (2,4).

Our case was evaluated primarily in terms of Kallmann's syndrome, due to mirror movements and the diagnosis of hypogonadotropic hypogonadism. Kallmann's syndrome is a neuronal migration disorder characterized by anosmia/hyposmia and hypogonadotropic hypogonadism. The clinical spectrum of isolated gonadotropin-releasing hormone deficiency includes various disorders, including Kallmann's syndrome, i.e., hypogonadotropic hypogonadism with anosmia, and its normosmic variation normosmic idiopathic hypogonadotropic hypogonadism, which represent the most severe aspects of the disorder (10,11). Additionally, mirror movements can also be seen. It's a rare genetic disorder that occurs in 1 in 8,000 in men and 1 in 40,000 in women (3,8,9). This syndrome also affects the olfactory system. This predicts that the development of other axonal pathways may also be affected, thus causing damage to the axonal pathways in the motor system. In cranial MRI, especially in coronal sections, the olfactory bulb may not be visible (3). The olfactory bulb was prominent in the cranial MRI in our case. Anosmia/hyposmia was not present. In functional MRI, it was seen that cortical motor areas were activated in the contralateral

of the both the hand that actively moved and the hand that contracted involuntarily.

In many studies studied on mirror movements, it has been shown that voluntary one-sided hand movement leads to bilateral motor cortex activation. Positron emission tomography, electroencephalography and simultaneous EMG, transcranial magnetic stimulation and functional MRI have been used in some studies to demonstrate this (3,10). Diffusion tensor imaging or functional MRI has recently come to the fore as neuroimaging to evaluate mirror movements. Changes in the corpus callosum volume, reduction in transcallosal motor fibers, and bilateral motor cortex activation can be seen in functional MRIs (1). We also think that when such complaints are encountered, functional MRI should primarily be kept in mind and preferred to show the etiopathology non-invasively, in a better and shorter time and to assist in the distinction between acquired and congenital forms.

Ethics

Informed Consent: Consent has been taken.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: N.T.H., V.K., A.A., M.Ç., Concept: N.T.H., V.K., A.A., M.Ç., Design: N.T.H., V.K., A.A., M.Ç., Data Collection or Processing: N.T.H., V.K., A.A., M.Ç., Analysis or Interpretation: N.T.H., V.K., A.A., M.Ç., Literature Search: N.T.H., V.K., A.A., M.Ç., Writing: N.T.H., V.K., A.A., M.Ç.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

Video 1.



<https://doi.org/10.4274/csmedj.galenos.2022.2022-1-8-video>

REFERENCES

1. Fasano A, Bologna M, Iezzi E, et al. Congenital mirror movements in a New Italian Family. *Mov Disord Clin Pract* 2014;1:180-187.
2. Cox BC, Cincotta M, Espay AJ. Mirror movements in movement disorders: a review. *Tremor Other Hyperkinet Mov (N Y)* 2012;2:tre-02-59-398-1.
3. Mayston MJ, Harrison LM, Quinton R, Stephens JA, Krams M, Bouloux PM. Mirror movements in X-linked Kallmann's syndrome. I. A neurophysiological study. *Brain* 1997;120:1199-1216.
4. Rawat SC, Pandey S. Clinical signs in movement disorders: phenomenology of mirror movements. *Ann Mov Disord* 2020;3:73-78.
5. Bonnet C, Roubertie A, Doummar D, Bahi-Buisson N, Cochen de Cock V, Roze E. Developmental and benign movement disorders in childhood. *Mov Disord* 2010;25:1317-1334.
6. Depienne C, Cincotta M, Billot S, et al. A novel DCC mutation and genetic heterogeneity in congenital mirror movements. *Neurology* 2011;76:260-264.
7. Barraud S, Delemer B, Poirsier-Violle C, et al. Congenital hypogonadotropic hypogonadism with anosmia and gorlin features caused by a PTCH1 mutation reveals a New Candidate Gene for Kallmann syndrome. *Neuroendocrinology* 2021;111:99-114.
8. Wen J, Pan L, Xu X, Wang J, Hu C. Clinical data and genetic mutation in Kallmann syndrome with CHARGE syndrome: case report and pedigree analysis. *Medicine (Baltimore)* 2018;97:e11284.
9. Dash PK, Raj DH. Biochemical and MRI findings of Kallmann's syndrome. *BMJ Case Rep* 2014;2014:bcr2014207386.
10. Manara R, Di Nardo F, Salvalaggio A, et al. Spectral signatures of mirror movements in the sensori-motor connectivity in kallmann syndrome. *Hum Brain Mapp* 2018;39:42-53.
11. Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. *Metabolism* 2018;86:124-134.